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EVALUATION OF THE ALLOMETRIC EXPONENTS IN PREDICTION 
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Background. Allometric scaling (AS) is widely used in predicting human clearance (CL) based 
on animal data. Substantial prediction errors have been commonly observed and various 
 
 
modifications to AS have not provided a broad reliable improvement. In this study, an extensive 
data set was assembled including animal and human systemic CL and physiochemical properties. 
The allometric exponents were calculated based on multiple species AS and single-species AS 
methods. The correlations between the allometic exponents and physiochemical properties were 
evaluated in an attempt to find covariates that may explain the inter-compound variability in the 
allometric exponents. Lastly, the statistical approaches in analyzing the allometric function were 
evaluated with the collected data.  
Methods. 1- A nonlinear mixed effect modeling (MEM) approach was performed to investigate 
the central tendency and distribution of AS exponents as well as to identify whether there are any 
correlations between the allometric exponent, and coefficient, with the physicochemical and drug 
metabolism and pharmacokinetics (DMPK) properties of the compounds. 2- Single-species AS 
was performed to estimate the single-species AS exponent distributions and their corresponding 
central tendencies. The correlation between the estimated single-species AS exponents and the 
physicochemical and DMPK properties of the compounds were also examined. 3- The 
methodologies of log-log transformation followed by linear regression (LL-LR) and direct 
nonlinear regression methods (NLS) with different weighting schemes on the AS power function 
were investigated. The central tendency and distribution of the allometric exponents were 
evaluated and compared across methods. Furthermore, the human CL prediction performance 
was evaluated among methods.  
Results. The estimated central tendency and distribution of AS exponents from the nonlinear 
MEM as well as the single-species AS approaches were consistent with literature reports. There 
were no significant correlations identified between the estimated AS exponents and the 
physicochemical or DMPK properties. The methods of LL-LR and the NLS with 1/w2 weighting 
 
 
(variance weighted by CL2 during the variance minimization process) results in the most similar 
allometric exponent with central tendency around 0.668 and provided the best human CL 
prediction among methods investigated.   
Conclusion. The knowledge gained in this work by extensive modeling and simulations 
contributed to a better understanding of the variability in AS exponents and better practice in 
performing AS in human CL prediction
1 
 
CHAPTER 1 
 
INTRODUCTION 
 
     Research on allometric scaling (AS) was introduced to biology about one century ago (1). AS 
was developed based on the principle that the relationship between organ size, regional perfusion 
and body weight of mammals could be characterized by a simple mathematical power law 
expression, Y = a (body weight)b, where Y is the parameter of interest, and a and b are the 
allometric coefficient and exponent, respectively. The observed power function is empirical, 
although there is some possible underlying physiological rational (2). In 1970, Dedrick and 
coworkers published the first paper to apply the concept of allometic analysis to drug disposition 
(3). The AS concept was fully developed and applied to the field of pharmacokinetics by 
Boxenbaum in the early 1980s (4). Since then, AS has been widely used in predicting human 
pharmacokinetic parameters, including drug CL based on in vivo animal pharmacokinetic data. 
However, it has been frequently reported that the simple body-weight based AS method using in 
vivo data from the common preclinical animal species fails to accurately predict human 
pharmacokinetics (5).  
     Over the years, great effort has been focused on how to improve the accuracy of AS. Various 
modified allometrically based scaling methods with correction factors, both empirical and 
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mechanistic in nature, have been proposed (6). Lave et al. proposed in vitro correction methods 
using hepatocyte data to normalize the in vivo CLs, which led to lower median deviation between 
the observed and the predicted CLs in man (7). Boxenbaum proposed a two-term power function 
approach (4). By scaling unbound CL, Feng et al. have shown an improved prediction for low 
CL compounds with extraction ratios of 0.3 or less (8). Boxenbaum suggested the incorporation 
of maximum lifespan potential (MLP) as a correction factor to normalize the metabolic capacity 
across species (4). Mahmood and Balian proposed using brain weight (BrW) as a correction 
factor to improve the prediction performance of the empirical AS method. Later, Mahmood 
proposed the rule of exponents (ROE) (9) which states that if the exponent from simple AS is 
between 0.55 and 0.70, simple AS is applied, if the exponent is between 0.70 and 1.0, the CL × 
MLP is applied and if the exponent is greater than 1.0, CL × BrW is applied (9). ROE is based 
on empirical observations, which suggest that when a large exponent is observed, it is likely that 
human CL based on animal data will be over-predicted. The MLP or BrW correction is thus 
utilized to correct the potential over-prediction (9). Recently, Tang et al. proposed an empirical 
model that provided better predictability for human CL than ROE by introducing the intercept 
concept and correcting for plasma binding differences between animals and humans (10). Other 
various approaches have been suggested to improve AS for compounds eliminated through renal 
or biliary excretion, or metabolism (11). 
      However, the applications of these correction factors in allometry have been controversial.  
The correction using in vitro metabolic data was successful in predicting human CL for ten 
extensively metabolized drugs (7). However, due to the small size of the dataset, whether such a 
correction method could improve the prediction for other compounds remains unknown. Feng at 
al. demonstrated by scaling unbound CL, there was a certain degree of success for improving the 
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prediction for low CL compounds,  however, the method failed to adequately predict CL for 
other compounds illustrating large vertical AS such as diazepam and valproate (8). The vertical 
AS refers to the situation where human CL was largely over-predicted by performing AS (12). 
Corrections based on MLP or BrW also demonstrate some success, but the number of examples 
is limited (13). Moreover, if used indiscriminately, these two approaches may worsen the 
prediction for certain compounds. This limitation led to the proposal referred to as ROE (13). 
ROE proposes selection criteria for the use of a MLP or BrW correction based on the values of 
exponents obtained from simple AS. However, due to the artificial cutoff of the exponent values 
and the small sample size (n = 38), it remains unknown on whether the ROE rule is generally 
applicable to other drugs. More recent studies by Nagilla and Ward demonstrated that the 
correction using MLP/BrW or the ROE in AS did not result in improvements in prediction of 
human CL. At the same time, the same authors proposed that a correction factor using monkey 
liver blood flow (LBF) provides better prediction than ROE (14). The LBF method for prediction 
of human clearance can be expressed in each of the preclinical species as a fraction of liver blood 
flow as follows: human clearance = animal clearance • (human liver blood flow/animal liver 
blood flow) (15). Additionally, Tang and Mayersohn pointed out that there is an intrinsic defect 
in using correction factors or ROE. Their work indicated that applying correction factors in AS 
was found to be equivalent to applying certain constant values that are predetermined on the 
basis of the species chosen and these correction factors bear no relationship to values of CL in 
the animals (16). 
     Another major inconsistency or controversy in AS is whether to use varying-exponent 
allometry or fixed-exponent allometry (17). AS extrapolation based on the empirical power 
function whose exponent and coefficient is estimated from animal species is termed as varying 
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exponent AS, which includes the simple AS and AS with any modifications and correction 
factors described above. The limitations and intrinsic defects of this approach have been 
extensively discussed (14). Currently, fixed-exponent AS is commonly used in the 
pharmaceutical industry. This approach includes data from one or two species (18) and any other 
general models having fixed exponents in the AS function. As noted in a recent publication by 
Tang et al, varying-exponent AS is not recommended. Various correction methods on the 
traditional AS should not be used as well (19). It has been postulated that the physicochemical 
properties of a compound may influence the success/failure of interspecies extrapolation. 
Individualization of the AS exponent based on the physicochemical factors of a certain category 
of compounds might be a promising direction.  
     One common criticism of AS is its empiricism, which is heavily dependent on the data 
selection and sample size. Generally AS methods have been developed based on relatively small 
sets of data (13). Inconsistency and controversies among different allometric methods or models 
were partially due to the limited data sets that have been analyzed. In this study, one of the major 
goals was to collect an extensive and diverse animal and human systemic CL data set, using 
multiple approaches to systemically investigate allometric exponents and their further application 
for human CL prediction.  
     This study included the largest allometric data set collected from the literature, with a total of 
251 drugs with systemic CL values in humans and rat or dog or monkey. Their corresponding 
physiochemical and certain drug metabolism and pharmacokinetic (DMPK) properties were also 
estimated. 
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     There are three major aims in this study. The first primary aim of this study was to investigate 
the potential correlations between the allometric exponents from multiple-species AS method 
and the physiochemical properties, with an attempt to identify covariates that may explain the 
inter-drug variability in AS relationship, thus enabling individualization of AS for better human 
CL prediction. A nonlinear mixed effect modeling (MEM) approach was applied to investigate 
the central tendency and distribution of AS exponents, as well as to identify whether there are 
any correlations between the allometric exponent/coefficient and the physicochemical and 
DMPK properties. Nonlinear MEM analysis is a one-stage approach, which simultaneously 
considers the population samples, rather than at the individual level, as a unit of analysis for the 
estimation of the distribution of parameters, sources of variability, as well as their relationship 
with covariates within the population. Overall, with the largest data set reported in the allometric 
field of pharmacokinetics and the rigorous analyses on the correlations of the physiochemical 
properties and allometric relationship, this work could demonstrate the impact of physiochemical 
covariates on the allometric predictions of clearance.      
     The second aim of this study was to evaluate the commonly used single species AS using the 
same data set. The estimated single species AS exponents were compared with generally 
accepted single species AS exponents. The correlations between the estimated AS exponents and 
the physicochemical or DMPK properties of the compounds were investigated. In addition, the 
uncertainties of the exponents of the single species methods obtained from this study were 
valuable as they provide a framework in incorporating the parameter uncertainty in predicting 
human CL using single species, which is highly recommended in real practice.  
     The last aim of this study was to evaluate the statistical methodologies in analyzing allometric 
functions, namely the log-log transformation followed by linear regression (LL-LR) and direct 
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nonlinear regression (NLS) with different weighting schemes. The log-log transformation of both 
sides of the empirical power function followed by linear regression (LL-LR) is the widely used 
approach when AS is adopted for human CL prediction. However, it should be noted that there is 
no theoretical basis for LL-LR being the most appropriate way to present the AS relationship and 
there is no prior knowledge that CL must follow a log-normal distribution in the allometric 
model (19). In this study, direct application of nonlinear regression with different weighting 
strategies was performed for the power function and the resulting exponents were compared to 
the LL-LR method. In addition, the prediction performance of direct nonlinear regression 
methods was compared to that of LL-LR method. Furthermore, the statistic indices, root mean 
square error (RMSE%) and BIAS%, which have not been evaluated in the allometric field, were 
assessed on its predictability in predicting human CL. Lastly, LL-LR analysis corrected by 
maximum life-span potential (MLP) and brain weight (BrW), which have been proposed and 
used by some researchers, were also being compared with the direct LL-LR method for human 
CL prediction. 
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CHAPTER 2 
 
IMPLEMENTATION OF NON-LINEAR MIXED EFFECT MODELING 
APPROACH IN ALLOMETRIC SCALING FOR HUMAN CLEARANCE 
PREDICTION 
 
1_Abstract 
Objective: Investigate whether there are any correlations between the allometric exponent, as 
well as the allometric coefficient, and the physicochemical properties and pharmacokinetics 
(DMPK) of different compounds based on an extensive scientific review of the literature. 
Methods: After mining the scientific literature, a total of 251 literature reported drugs with 
intravenous pharmacokinetic parameter (CL) values in humans and rat or dog or monkey (at least 
three species including humans) were collected and were used as the MEM model dataset. The 
physicochemical and DMPK properties of each drug were estimated.  The nonlinear MEM 
modeling approach with NONMEM was applied to the data to investigate the central tendency 
and distribution of allometric scaling (AS) coefficient and exponent. An investigation was 
conducted between the AS exponent and coefficient (CL at unit weight) with the 
physicochemical and DMPK properties of drugs to identify potential significant covariates.   
10 
 
Results: A nonlinear MEM AS model with additive residual error was developed. The estimated 
central tendency and distribution of AS exponent was consistent with literature reports. Polar 
surface area (PSA) was identified as statistical significant covariate for AS coefficient by 
explanation of 5.7% of inter-drug variability for AS coefficient from 104% to 98.3%. However, 
compared to the 98.3% remained un-explained inter-drug variability (IDV), this 5.7% IDV 
finding may not have much practical usage.   
Conclusion: By using MEM modeling for allometric scaling, the central tendency and 
distribution of AS exponent was systemically investigated and confirmed the empirical adopted 
value. None of the physicochemical and DMPK properties investigated were found to 
significantly affect the prediction of human CL by AS. 
  
11 
 
2_Introduction 
Allometric Scaling  
     In drug discovery, accurate human pharmacokinetic parameters prediction, particularly 
clearance (CL) is essential not only to project efficacious first-in-man doses but also facilitate in 
predicting appropriate dosing frequency and safety margin as well as obtaining insights into 
differentiation of available clinical candidates (1). Various methods have been proposed and 
applied over the past decades to predict human CL, such as scaling from in vitro human tissue or 
in vitro animal data, in vivo interspecies scaling and physiologically based pharmacokinetic 
modeling (2-8). As one of the most widely used approaches, allometric scaling (AS) has been 
explored for the prediction of human drug clearance (CL) based on the measure values of CL in 
animal species (9).  
     AS was developed based on the principle that the relationship between organ size, regional 
perfusion and body weight of mammals could be characterized by a simple mathematical power 
expression, Y = a Wb, where Y is the parameter of interest, W is body weight and a and b are the 
allometric coefficient and exponent, respectively. Because of the empirical nature of AS, it has 
been frequently reported that the simple body-weight based AS method using in vivo data from 
the common preclinical animal species fails to accurately predict human pharmacokinetics (10). 
Over the years, numerous modifications have been proposed to improve the AS prediction 
capacity (11)(12). Lave et al. proposed in vitro correction methods using hepatocyte data to 
normalize the in vivo CL, which led to lower median deviation between the observed and the 
predicted CL in man (13). By scaling unbound CL, Feng et al. showed an improved prediction 
for low CL compounds with extraction ratios of 0.3 or less (14). Boxenbaum suggested the 
incorporation of maximum lifespan potential (MLP) as a correction factor to normalize the 
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metabolic capacity across species (15). Mahmood and Balian proposed using brain weight (BrW) 
as a correction factor to improve the prediction performance of the empirical AS method. Later, 
Mahmood proposed the rule of exponents (ROE) (16). Recently, Tang et al. developed an 
empirical model that provided better predictability for human CL than ROE by introducing the 
intercept concept and correcting for plasma protein binding differences between animals and 
humans (17). Other various approaches have been suggested to improve AS for compounds 
eliminated through renal or biliary excretion, or metabolism (18-22).  
     However, the applications of these correction factors in allometry have been controversial.  
The correction using in vitro metabolic data was successful in predicting human CL for ten 
extensively metabolized drugs (13). However, due to the small size of the dataset, whether such a 
correction method could improve the prediction for other compounds remains unclear.  Feng et 
al. demonstrated that by scaling unbound CL, there was a certain degree of success for 
improving the prediction for low CL compounds with extraction ratios of 0.3 or less (14). 
However, the method failed to adequately predict CL for other compounds illustrating large 
vertical AS such as diazepam and valproate. The vertical AS refers to the situation that human 
CL was largely over-predicted by performing AS (23).  Corrections base on MLP or BrW also 
demonstrated some success, but the number of examples is limited (24). Moreover, if used 
indiscriminately, these two approaches may worsen the prediction for certain compounds. This 
limitation led to the proposal referred to as ROE (16). ROE proposes selection criteria for the use 
of a MLP or BrW correction based on the values of exponents obtained from simple AS. 
However, due to the artificial cutoff of the exponent values and the small sample size (n = 38), 
further investigation on whether the ROE rule is generally applicable to other drugs is needed. 
More recent studies by Nagilla and Ward demonstrated that the correction using MLP/BrW or 
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the ROE in AS did not result in improvements in prediction of human CL (20)(25)(26). 
Additionally, Tang and Mayersohn pointed out that there is an intrinsic defect in using correction 
factors or ROE (27). Their work indicated that applying correction factors in AS was equivalent 
to applying certain constant values that are predetermined on the basis of the species chosen and 
these correction factors bear no relationship to values of CL in the animals.  
     It has been postulated that the physicochemical properties of a molecule may have an 
important impact on its pharmacokinetic fate in the body. Therefore, we hypothesized that 
physicochemical properties of drugs could influence the success of interspecies extrapolation. 
Individualization of the AS exponent based on the physicochemical factors of a certain category 
of compounds could be a promising direction.  
The Nonlinear MEM Analysis 
     Nonlinear mixed effect modeling (MEM) analysis is a one stage approach, which 
simultaneously considers the population samples, rather than at the individual level, as a unit of 
analysis for the estimation of the distribution of parameters and their relationship with covariates 
within the population. The word “mixed” refers that the method simultaneously evaluates both 
fixed (such as covariate effect etc.) and random effects (such as inter-drug variability and intra-
drug variability etc.).  
     In population pharmacokinetics, the MEM approach is ideally suited for analyzing data from 
large clinical trials, where only a few samples are available for each subject (28). This technique 
identifies individual-specific characteristics that impact the disposition of a drug. In addition, the 
results are more generalizable than those of the traditional methodology because a greater 
number of subjects are evaluated (29).  
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     In this study, an exhaustive literature search was conducted and an extensive database of 
intravenous drug CLs in different species was compiled. The physicochemical properties of each 
collected compound were estimated. With this large and diverse database, using the population 
nonlinear mixed effect modeling (MEM) analysis, the potential impact of physicochemical and 
drug metabolism and pharmacokinetics (DMPK) properties on AS exponents as well as the 
coefficient (CL per unit body weight) were investigated. Any significant and meaningful 
correlations between the allometric exponent and other characteristics of the drugs, if found, are 
expected to greatly improve the predictions of CL, since the exponent for each drug may be 
individualized to best represent the allometric relationship between animals and humans.  
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3_ Materials and Methods 
Data collection 
     Two hundred and fifty one sets of intravenous administered drug CL data were collected from 
the literature (Table 1.). For each selected drug, there are at least three animal species CL values 
(rat, dog, monkey and human). The CL values included in the database were systemic clearance 
determined following intravenous drug administration. This data collection was initiated based 
on a few major review and/or research papers on AS (Obach, Ward, Tang et al.) (30)(31).  Also a 
general search with key words such as “allometric scaling”, “allometry PK prediction”, etc. were 
performed on PubMed to capture some individual reports that were not included in the review 
papers. During the data searching and assembling process, the original literature reporting CL 
values for each individual drug across species were revisited and evaluated to ensure the quality 
of the data collection, including the following major considerations and efforts. The first effort 
was to ensure the pharmacokinetic calculations of CL. For example, CL should be calculated 
from the parent compound data, as a few limited papers may have reported the CL calculated 
from the total radioactivity. For another example, the CL calculation should be based on the area 
under the curve (AUC) infinity or steady-state AUC. If these two AUCs were not reported and 
used for CL calculations, an examination was given to the time-concentration profile to make 
sure the AUC extrapolated should be a minor contribution to the AUC infinity. The second effort 
was around the PK linearity. PK in animals (occasionally) and PK in humans (many times) were 
done at multiple doses. If there were indications of nonlinear PK, the CL in animals and humans 
were selected based on the values obtained at allometrically comparable doses across species. 
The term of “allometric comparable” means the doses after scaling by the body weights with an 
allometric exponents roughly at 0.67. For example, an 1 mg/kg dose in rats was approximately 
16 
 
comparable to 0.15 mg/kg dose in humans. The third effort was mainly given to the 
examinations of human PK on a numbers of important factors, such as human population, co-
medications, etc. Generally the CL values should be obtained from the healthy animal 
populations, as animal PK was generally done in healthy population. Also most CL values were 
obtained from the studies with single drug administrations. In cases of studies with co-
medications, assessment was made, based on general DMPK properties of the drug of interest, 
that there was no significant DDI involved. For certain instances, there were multiple reports (for 
example, PK from single ascending doses and multiple ascending doses were available) for the 
same compound, a weighted average was estimated taking into the consideration of the study 
size. Some additional efforts were made by digitalizing the original plots and re-analyze the PK 
data when there were apparent mismatches or questions between the PK parameters and time-
concentration profiles with DigitizeIt version 2.0.0 (available at  http://digitizeit.soft112.com/) 
and Phoenix version 1.3 (Certara L.P. Cary, North Carolina).   
Physicochemical and DMPK Properties Estimation 
     The two-dimensional physicochemical and topological descriptors of the collected 
compounds were computed with a proprietary program (Chemoinformatics, Monika Five v 1.2, 
Merck), which predicts physicochemical and ADME properties based on chemical structures. 
After an initial screening, a total of 17 physicochemical and drug metabolism and 
pharmacokinetics (DMPK) properties of drugs were selected for MEM modeling. The 
physicochemical and DMPK properties of drugs were: 1) molecular weight (MW);  2) hydrogen 
bond acceptor count (HBA); 3) hydrogen bond donor count (HBD);  4) number of non-hydrogen 
atoms (nonH);  5) polar surface area (PSA); 6) rotatable carbon bond (RCB); 7) calculated 
logarithm of the octanol-water partition coefficient (cLogP); 8) estimated logarithm of the 
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octanol-water partition coefficient at pH 7.0 based on HPLC assay (elogD); 9) calculated 
logarithm of the octanol-water distribution coefficient at pH 7.4 (clogD); 10) ionization status 
(%IONI);  11) oral absorption property (good, moderate, bad)(OrlA); 12)  plasma protein 
binding (PPB); 13) central nervous system absorption (CNSa); 14) apparent permeability 
through cell membrane (Papp); 15) human P-glycoprotein transporting property (PGPh); 16) rat 
P-glycoprotein transporting property (PGPr); and 17) elimination pathway (ELIM).  These terms 
are defined and discussed below. 
      The molecular weight was calculated as the mean natural isotope weight of the compound. 
The hydrogen bond acceptor count and hydrogen bond donor were computed by substructure 
search. The number of non-hydrogen atom represents the non-hydrogen atom count. The polar 
surface area  demonstrates the topological polar surface area according to Ertl et.al (32). The 
rotatable carbon bond represents the single bond between heavy atoms that are both not in a ring 
and not terminal. The logP is a widely used measurement of the lipophilicity of a compound and 
therefore an important physico-chemical parameter in relation to its pharmacological behavior, 
such as membrane permeation and plasma protein binding. The calculated logP (clogP) was the 
calculated partition coefficient of the neutral form of the compound in octanol/water based on the 
proprietary logP calculation system (Biotyte). The estimated logD (elogD) was evaluated at pH 
7.0 based on high-throughput HPLC assay. The clogD represents the calculated logarithm of 
octanol /water distribution coefficient at pH 7.4. The ionization status indicates the percentage of 
the molecule will be ionized at the given reference pH and is derived from the individual pKa 
values of ionizable groups in the molecule. The oral absorption characteristics was predicted 
based on a new in silico classification model, which was derived from the classic Lipinski Rule 
of 5 (33). The plasma protein binding was classified based on the measurement of how much of a 
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given compound is bound to plasma proteins versus how much is free in solution. Central 
nervous system absorption was classified based on 6 relevant calculated properties - MW, clogP, 
H-acceptors, H-donors, PSA and Rotatable bonds - with respect to how well the compound is 
likely to pass the blood-brain barrier (BBB)(34). The apparent permeation through the cell 
membrane was calculated using a random forest quantitative structure–activity relationship 
models (QSAR models).  The apparent Human and rat P-glycoprotein (PGP) transport properties, 
measured in an uM assay and calculated by a random forest QSAR model. This model, based on 
human or rat PGP data expressed as BA: AB ratios, tried to predict the actual value of the 
BA:AB ratio. Being collected from the literature reports, the elimination pathway was 
characterized as by metabolism or excretion or by both. The compounds that are only excreted 
unchanged through kidney or bile are categorized to be “excretion”. The compounds metabolized 
before renal or biliary excretion are considered under “metabolism” type. For the compounds 
that have percentage of metabolism and excretion are categorized to be “both”. 
MEM Modeling Approach on AS  
     The relationship between the AS parameters and the above mentioned physicochemical 
characteristics was investigated using the population nonlinear MEM modeling approach based 
on the literature collected pharmacokinetic data following intravenous drug administration. For 
each drug, there were CL values in at least 3 species (rat, dog, monkey and human). This 
population-based method was evaluated to provide a more reliable AS exponent and coefficient 
central tendency and distribution estimation, examine the within-drug and between-drug 
variability, as well as identify both statistically significant and practically meaningful covariates 
(physiochemical and DMPK properties) on the AS exponent or coefficient.  Statistically and 
practically significant covariates may be expected to improve the predictions of CL, since the 
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exponent for each drug may be individualized to best represent the allometric relationship 
between animals and humans.  
     The population MEM analysis of AS on the combined data set was performed by using 
NONMEM® (version VII, Icon Corp, Hanover, MD)(35). Several estimation methods (first-order 
approximation (FO), first-order conditional estimation (FOCE) and first-order conditional 
estimation with interaction (FOCEI)) were explored. Compared to FO method, the FOCEI 
method can provide less biased results. During the preliminary modeling exploration, the FOCEI 
approach did converge smoothly. Therefore, the FOCEI method was chosen as the estimation 
method and was employed for all model runs. The maximum likelihood ratio test was used to 
discriminate between alternative models. An objective function value (OFV) decrease of 3.84, 
6.64 and 10.83 units were considered significant for P < 0.05, P < 0.01 and P < 0.001, 
respectively (χ2 degree of freedom (df)  = 1).  
Basic structure model of AS 
     By adopting the commonly used approach for AS, the basic structural model of the AS 
function was written as: 
Log (CLij) = log (ai) + bi × log (Wij)      (1)  
In Eq. (1), CLij is the CL for jth species in ith drug, Wij is the body weight for jth species in ith 
drug, and ai is the allometic coefficient (intercept of the log-log transformation followed by 
linear regression (LL-LR) equation) and bi is the allometric exponent (slope of the LL-LR 
equation) for ith drug.  
Inter-drug variability  
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     In this model component, the individual drug parameter estimates were modeled as a function 
of typical value for the population and individual random deviations. Inter-drug variability was 
assumed to be normally distributed with mean zero and variance of ωa2 and ωb2 for allometric 
coefficient and exponent, respectively. The inter-drug variability of the MEM model parameters 
were explored for each one of the functions listed below Eq. (2), take the allometric exponent 
(coded as the SLOP in the basic structure model) as an example: 
Exponential: 𝑆𝐿𝑂𝑃 = 𝑇𝑉𝑆𝐿𝑂𝑃 × 𝑒𝜂𝑠𝑙𝑜𝑝 
Additive: 𝑆𝐿𝑂𝑃 = 𝑇𝑉𝑆𝐿𝑂𝑃 + 𝜂𝑠𝑙𝑜𝑝 
Proportional: 𝑆𝐿𝑂𝑃 = 𝑇𝑉𝑆𝐿𝑂𝑃 × (1 + 𝜂𝑠𝑙𝑜𝑝)        (2) 
Where, TVSLOP is the typical value of the allometric exponent for the drug population; SLOP is 
the individual parameter estimate; 𝜂𝑠𝑙𝑜𝑝  is the inter-drug variability term on SLOP, representing 
the difference between the individual parameter estimate and the population mean. The 
exponential function was selected after initial exploration for inter-drug variability of the 
allometric SLOP and coefficient. Non-diagonal entries for ηs were assumed to be zero. 
Intra-drug variability  
     The difference between the predicted CL and observed CL is defined as residual variability, 
which is comprised of but not limited to intra-drug variability, experimental error, and bio-
analytical analysis error and/or model misspecifications. It was modeled using additive, 
proportional and combined error structure as described below Eq. (3):  
Additive error: ijijij LCCL ε+=

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Proportional error: )1( ijijij LCCL ε+=

 
Combined additive and proportional error: ')1( ijijijij LCCL εε ++=

          (3) 
Where ijCL  was the j
th observed CL in the ith drug, ijLC

was the corresponding model predicted 
CL, and ijε  (or 
'
ijε ) was a normally distributed random error with a mean of zero and a variance 
of σ2. Based on the goodness of fit, the additive error function was selected for the description of 
intra-drug variability in this investigation.  
Covariate model development  
     A core objective of this MEM modeling approach investigation on the AS relationship was to 
identify the sources of variability from the physicochemical and DMPK properties of drugs 
which could significantly affect the AS exponent and coefficient estimation. Quantitative 
assessment of the relationship between covariates and AS exponent and coefficient is important 
for drug development because it could potentially provide critical information on categorized AS 
exponent values for different drug categories, then assist in more accurate human CL prediction.  
     Covariate identification and its selection criteria - The effect of an individual drug’s specific 
physicochemical and drug metabolism and pharmacokinetics (DMPK) properties, cLogP, 
molecular weight, polar surface area, clogD and others were tested on AS parameters during the 
covariate model development. The covariate models were developed by a forward inclusion / 
backward elimination using the maximum likelihood ratio test criteria. For the forward inclusion 
stage, covariates that were significant at the 0.01 level were retained in the model (χ2, ΔOFV = -
6.64, df = 1). Once all the covariates that are significant at the 0.01 level have been included in 
the model, a backward elimination process was conducted. A significant level of 0.001 was used 
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for the backward elimination (ΔOFV = -10.83, df = 1). The backward elimination process was 
repeated until all remaining covariates were significant (p<0.001). Covariate influence on inter-
drug variability and goodness of fit were also evaluated. Covariate factors should also have 
clinical or practical relevance. 
     Incorporation of covariates - The covariates can usually be classified as continuous 
covariates such as cLogP and molecular weight and discrete covariates including oral absorption 
property, elimination pathway and others. These two types of covariates were incorporated into 
the model as described below Eq. (4) (5). Take the allometric exponent (coded as the SLOP in 
the basic structure model) as an example: 
The incorporation of a continuous covariate for the AS exponent (SLOP)  
Cov
CovSLOP MedCovTVSLOP
θθ )/(×=  
 𝑆𝐿𝑂𝑃 = 𝑇𝑉𝑆𝐿𝑂𝑃 × 𝑒 slopη                                  (4) 
Where TVSLOP is the population estimate of the AS exponent for an individual drug having a 
specific covariate; θSLOP is the population estimate for AS exponent without a covariate effect; 
Cov is the continuous covariate that is affecting AS exponent; θCov is the constant describing the  
association between covariate and typical value of parameter estimates; and MedCov is the median 
value of Cov; SLOP is the individual estimate of AS exponent, which is the population estimate 
for AS exponent incorporating the covariate and inter-individual drug variability; slopη  is the 
inter-individual variability term for AS exponent. 
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The incorporation of a discrete covariate involves assigning a numeric value to the covariate (e.g. 
oral absorption property, low = 1, moderate = 2, high = 3). The incorporation of this covariate is 
shown below: 
IF (oral absorption property.EQ.1): TVSLOP= θlow 
IF (oral absorption property.EQ.2): TVSLOP = θmoderate 
IF (oral absorption property.EQ.3): TVSLOP = θhigh 
Model evaluation   
     The aim of model evaluation was to determine whether the model is a good description of the 
original data set. The model evaluation methods in this project are listed below. 
Assessment of Goodness-of-fit  
     Graphical inspection of model predictions versus observations was performed through all 
steps of model development to assess the diagnostic plots for model goodness-of-fit. Diagnostic 
plots include observed CLs versus population prediction (PRED), observed CLs versus 
individual prediction (IPRED), conditional weighted residuals (CWRES) versus PRED, and 
CWRES versus log (WT). Model stability inspection was also conducted through all model steps 
for conditional number, which was defined as the ratio of the largest Eigen value to the smallest 
Eigen value and was calculated using the PRINT=E option on the $COV in the NONMEM 
control stream (ideally be ≤|1000|, as a condition number exceeding 1000 is indicative of ill-
conditioning of the model). Additionally, the final developed model was also evaluated using a 
bootstrap technique (resampling with replacement), as suggested by Efron (36).  
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Statistical Assessment for Prediction Performance 
     The predictability of the nonlinear MEM model on AS for individual drug CL was assessed 
by average fold-error (AFE) and the average absolute fold-error (AAFE)(37): 
 
 
 
AAFE and AFE are measures of precision and bias of the overall prediction, respectively. In the 
equations, N represents the total number of drugs in the database. AFE representing the 
geometric mean of fold-errors allows the measurement of overall bias in both directions. As a 
result, AFE less than or greater than 1 indicates an overall under or over-prediction, respectively. 
The closer to 1, the better precision AAFE demonstrates. 
 
4_Results  
     A total of 251 drugs with literature reported CL values in humans and rat or dog or monkey 
were collected and were used as the MEM model dataset. The final database with the literature 
collected CL values in all species, the estimated physicochemical and DMPK properties, and 
literature reported elimination pathway information is shown in Table 1. The compounds 
compiled in this study encompass a wide variety of structures, and span a broad range of 
fundamental physicochemical properties and therapeutic usage. For human CL, the data span 
over a considerable range from 0.0037 to 1070 ml/min, however, approximately 80% of human 
N
)errorfoldlog(
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∑ −
=
N
)errorfoldlog(
10AAFE
∑ −
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CL values of the compounds resided in the range of 1 and 10 ml/min.  Among the 251 drug data 
base, 137 drugs are primarily metabolized, 91 drugs are eliminated by renal or biliary excretion 
and 23 drugs are eliminated by both pathways.   
Basic Structure Model 
     The basic structure model parameter estimates are shown in Table 2. The AS exponent was 
estimated to be 0.629 (% Relative Standard Errors (RSE) = 2.93) with inter-drug variability (IIV) 
estimated to be 41.3% and the AS coefficient as estimated to be 2.06 (%RSE = 7.80) and the IIV 
to be 104%. 
Final Covariate Model 
     The key challenge of building a covariate model is over-parameterization, which could lead to 
convergence difficulties and covariance step failures. When two or more potential covariates are 
highly correlated, the best recommended strategy is to select a reduced set of covariates that have 
the greatest scientific plausibility to reduce co-linearity among continuous covariates. Therefore, 
in this study, for the 17 physicochemical and DMPK properties estimated for each compound, 
correlations among those physicochemical and DMPK properties across the drug population 
were performed to avoid over-parameterization during covariate modeling. As a result, hydrogen 
bond acceptor count (HBA), hydrogen bond donor count (HBD) and number of non-hydrogen 
atom (nonH) were found to be closely related to molecular weight (MW). Therefore, only 
molecular weight was kept in the data set to represent the chemical size character of the 
corresponding compound. A similar high correlation was identified between human P-
glycoprotein transporting property (PGPh) and rat P-glycoprotein transporting property (PGPr). 
Human P-glycoprotein transporting property (PGPh) was thereafter chosen to be kept in the data 
26 
 
set to represent the P-glycoprotein transportation properties. At the same time, the calculated and 
the estimated logarithm of octanol /water partition coefficient both represent the lipophilicity of a 
compound and therefore only the estimated logP value was chosen in the main data set. As a 
result, a total of twelve physicochemical and DMPK properties were kept for further covariate 
modeling. Statistics and the distributions of the calculated physicochemical and DMPK 
properties which were used for the final model development are shown in Table 3. and Figure 1. 
     The covariate modeling started with graphical exploration for potential relationships between 
final basic structure model parameters and each potential covariate, scatter plots of inter-drug 
variability of the AS exponent and coefficient from basic structure model (ETAs) versus 
continuous covariates and box plots of ETAs versus categorical covariates were investigated 
(Appendix 1.). As a result of the graphical exploration, no apparent correlations were identified 
for any pair of ETAs versus potential covariates. However, there were weak trends identified 
between the AS coefficient and PSA, RotB, PGPh and ELIM as well as AS exponent with clogP, 
Papp, Ppb, PGPh, Psa, RotB and ELIM being identified. Therefore, during the final covariate 
model development, these potential covariates were introduced to each parameter one by one by 
power or exponential functions. Based on the covariate modeling strategy described in the 
method section, after forward addition procedures, the combination of PSA + RotB was 
identified to be a significant covariates for AS coefficient and Ppb was identified to be 
significant covariate for AS exponent. Following backward elimination steps, PSA was 
identified to be the statistically significant covariate of AS coefficient by resulting in a drop in 
OFV by 23.6 points (p < 0.001). The final model parameter estimations are shown in Table 2. 
The AS exponent was estimated to be 0.628 (%RSE = 2.94) with inter-drug variability (IDV) 
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estimated to be 41.3% (%RSE = 29.2). The AS coefficient as estimated to be 2.08 (%RSE = 7.44) 
and the IIV to be 98.3%.  
     With the consideration of the covariate effect from PSA, the inter-drug variability of the AS 
coefficient dropped from the base model of 104% to the final model at 98.3% , which means 
PSA helped explain about 5.7% of the inter-drug variability on AS coefficient. From a practical 
perspective, this provides no significant improvement for the explanation of AS coefficient 
variability. The covariate effect from PSA on AS coefficient did not help to reduce inter-drug 
variability of AS exponent, which was kept constant from the basic structure model to the final 
model at 41.3% (%RSE = 29.2). The estimates of shrinkage for inter-drug variability on AS 
exponent and coefficient were all under 5% and the shrinkage for residual variability was high 
for both base and final models, which was caused by fixing residual variability. During initial 
modeling process, both IDV and residual variability was open for estimatio, the IDV estimation 
was not stable with big shrinkage. After an initial exploration of a range of different residual 
variability, the 18% residual variability was selected for both base and final based on the model 
stability, shrinkage for residual variability and reasonably estimation of inter-drug variability. 
     The evaluation of the final AS nonlinear MEM model was done by assessment of goodness of 
fit (GOF) in Figure 2. The observed CL values agreed well with the final model predicted CL 
values. The conditional weighted residuals did not reflect any systematic trends, suggesting that 
the final model accurately reflects the data. From the plots (A) and (D) in Figure 2, 
phencyclidine which has the smallest PSA in the data set (PSA = 3 Å) demonstrated a different 
population prediction versus observation correlation compared to other drugs in the plots. This is 
because, compared to basic structure model (GOF plots not shown), PSA was selected to be a 
significant covariate on AS coefficient and had been included in the final model. Case deletion 
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test was therefore performed on phencyclidine by repeatedly modeling the basic structure model 
and final covariate model with and without phencyclidine.  As a result, phencyclidine did not test 
to be a significant outlier. The conclusion of PSA as a statistical significant covariate had not 
been influenced by including and excluding phencyclidine from the data set. Therefore, 
phencyclidine was kept in the data set for continuing AS modeling and simulation purposes. 
     The distribution of observed human CLs (Plot a. and b. in part 1) as well as the final model 
predicted human CL distribution (P lot c. and d. in part 2) for compounds in this study are 
illustrated in Figure 3. The log transformed observed or predicted CLs illustrated that human 
CLs follow a log normal distribution. A similar central tendency and distribution on log-
transformed human CLs was identified between the final AS model prediction and the 
observation, which demonstrated the final model did a fairly good prediction of human CLs.  
     The robustness of the basic structure model and the final covariate model were also assessed 
with the nonparametric bootstrap procedure (Table 2). Of the 1000 replicates for both the basic 
structure model and the final model, 100% converged successfully, indicating good model 
stability. The median parameters obtained from bootstrap replicates for both base and final 
models were similar to the NONMEM model estimates and the parameters appeared to be 
reasonably well estimated.  Based on the final AS model, the individual drug fits of the observed 
versus model predicted CLs across species and drugs in this data set were demonstrated in 
Appendix 2. For most of the drugs in the data set, the AS final model predictions did capture the 
observed CLs well.  
     In this study, AFE and AAFE were calculated to examine the prediction capacity of the final 
model. The AFE value was estimated to be 1.12, which indicates a slight overestimate, but a 
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fairly good prediction. The AAFE was calculated to be 1.41, which demonstrates a relatively 
good precision for the CLs prediction. The final model estimated AS exponents based on the 
diverse data base were also investigated. The central tendency (median = 0.663) and the 
distribution of the model predicted AS exponents were very similar to the literature review 
results by Hu et al (38). The comparison is shown in Figure 4.   
 
5_Discussion 
     In this study, CL values for humans and rat or dog or monkey were collected from the 
literature. This diverse database forms a unique basis for the investigation of AS for human CL 
prediction through a nonlinear MEM approach aiming to get a deeper understanding of the 
relationship between commonly investigated drug physicochemical and DMPK properties and 
pharmacokinetic fate of drugs in the body.  
     Physicochemical properties and their impact on drug pharmacokinetics and metabolism is a 
broad and complicated topic. There are no simple and unifying indicators which can explain the 
processes of drug metabolism and excretion. Over the years, quite a few groups of researchers 
have investigated the relationship of DMPK and drug physicochemical properties(39)(40). 
However, no relationship has been identified between CL and any chemical structure 
characteristics. Most of these studies have been conducted in a direct correlation level with 
limitations due to relatively small data set sizes.  
     As a major part of this study, a nonlinear MEM model of AS for human CL prediction was 
developed. The final model demonstrates a fairly good capture of the observed CL values in 
different species across a diverse drug population.  The central tendency of the AS exponent 
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estimated out of this modeling project confirmed the empirical AS exponent value generally used 
in the AS field and has provided a solid evidence for further usage.  No practically meaningful 
covariate was identified for the AS exponent. For the AS coefficient, the small IIV variability on 
AS coefficient that has been explained by PSA is not at a practically meaningful level for drug 
development.  
     The population analysis, nonlinear MEM approach, is a powerful tool superior to various 
traditional analysis methods in certain aspects.  It is a one stage approach by considering the 
population samples (rather than the individual) as a unit for the estimation of the distribution and 
central tendency of parameters, variability and their relationship with covariates within the 
population. In this study, with the advanced modeling approach, there was still no significant 
covariate identified for the AS exponent (out of the 12 physicochemical and DMPK properties 
estimated for the compounds in the database). This result may indicate that most likely there are 
indeed no correlations between those physicochemical and DMPK properties and CL allometric 
exponent values. Lipophilic drugs are usually eliminated by liver metabolism followed by biliary 
excretion or by active excretion by transporters. For this type of compound, drug CL is a series 
of biochemical processes and may depend more on the functionalities of drug transporters and 
metabolic enzymes rather than the drug chemical structures. For most hydrophilic drugs, such as 
those antibiotics with logP values small than 0, passive renal excretion is usually the elimination 
route, which follows well the allometric law for the flow parameters (41). Most drugs studied 
here or in the current discovery/development pipeline, are more lipophilic, so metabolic 
elimination dominates, therefore, physiochemical properties may not be the major factors in 
determining the interspecies difference and thus may not be able to explain the variability in 
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allometric exponents. On the other hand, volume of distribution may have a greater dependence 
on the physicochemical properties of a drug (42).  
     For a future direction, in order to get good human CL predictions for compounds under 
development, a better understanding of the drug metabolic pathway and possible transporters 
across species, might improve human CL prediction. 
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Table 1. Drug clearance values in different species with physicochemical and DMPK properties 
 
Compound 
Name 
human 
CL 
(mL/mi
n) 
rat CL 
(mL/mi
n) 
dog 
CL(m
L/min
) 
monkey 
CL 
(mL/min) 
CNSa 
(0-1) 
Elog
D 
Papp 
(10^-6 
cm/sec
) 
PGPr 
(BA:AB 
ratio) 
PPB 
(0-
100%) 
PGPh 
(BA:AB 
ratio) 
OrlA ClogP 
MW 
(Da) 
HB
A 
HB
D 
PSA 
(Å2) RCB 
non
H 
Clog
D 
%IONI 
(0-
100%) 
ELI
M Ref 
Acecainide 
(N-
acetylprocai
namide) 
280 9.24 76.8 --- 0.94 0.73 21 2.5 38 1.7 Good 1.6 277.4 3 2 61 7 20 -0.6 99.6 excr (30)(43) 
Acetaminop
hen 350 4.95 48 36.5 0.98 -0.4 33 0.55 58 0.58 Good 0.5 151.2 2 2 49 1 11 0.5 0 
meta
b 
(30)
(44) 
Aciv icin 48.3 2.112 16.8 11.5 0.92 0.17 3.9 0.58 28 0.91 Bad -1.6 178.6 5 2 85 2 11 -4.1 100 excr (30)(45) 
Actisomide 475.3 15.84 144 100 0.94 2.9 30 1.5 93 1.2 Moderate 5.4 369.5 4 0 36 6 27 2.6 99.9 both 
(30)
(46)
(47) 
Acy clovir 329 2.211 73.2 44 1 -0.45 8.1 0.68 25 0.68 Bad -2.4 225.2 6 3 115 4 16 -2.4 1 excr (30)(48) 
Adef ovir 259 7.26 63.6 80 0.83 0.53 4.2 0.82 25 1 Bad -1.9 273.2 8 3 146 5 18 -5.8 100 excr (30)(49) 
Albuterol 
(salbutamol) 546 32.01 384 --- 0.55 -1.6 10 0.93 23 0.96 Moderate 0.1 239.3 4 4 73 5 17 -2.2 --- excr 
(30)
(50) 
Alf entanil 273 9.57 228 160 0.99 2.1 25 4.2 79 2.8 Good 2.1 416.5 6 0 81 9 30 1.8 67 metab 
(30)
(51) 
Almotriptan 623 18.414 342.24 200 0.96 1.7 31 2.6 63 1.3 Good 1.8 335.5 3 1 56 6 23 -0.1 99.2 excr 
(30)
(52) 
Amif loxacin 319.2 3.96 54 36.5 0.23 0.098 8.4 2.2 47 1.5 Good 1.4 334.4 7 2 76 3 24 0.4 100 excr 
(30)
(53) 
Amikacin 77 1.782 42 --- 0 1.4 1.9 4.2 42 3.7 Bad -6.3 585.6 17 13 332 10 40 -11.6 100 excr (30)(54) 
Aminocyclo
propanecarb
oxy lic Acid 
105 1.056 4.8 15.5 0.97 1.1 3.5 0.66 23 0.7 Bad -3.4 101.1 3 2 63 1 7 -5.9 100 excr (30)(55) 
Amiodarone 133 8.25 348 --- 0.33 3.1 17 2.7 99.4 1.5 Bad 8.9 645.3 3 0 43 11 31 7 99 metab 
(30)
(56) 
Amlodipine 490 40.26 132 --- 0.62 2.1 11 4.9 85 2.5 Good 3.4 408.9 7 2 100 10 28 1.9 97 metab 
(30)
(57) 
Amoxicillin 231 5.61 40.8 --- 0 -0.18 3.1 3 62 2.1 Bad -1.9 365.4 7 4 133 4 25 -5.3 100 excr (30)(58) 
Amphetamin
e (-d) 679 29.7 85.2 --- 1 0.76 24 0.56 56 0.68 Good 1.7 135.2 1 1 26 2 10 -0.7 99.7 both 
(30)
(59) 
Amphoterici
n B 11.9 0.627 10.8 21 0.08 2.7 3.2 5.8 87 5.3 Bad -0.6 924.1 17 11 299 3 65 -3.2 100 excr 
(30)
(60) 
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Ampicillin 196 6.27 109.2 --- 0 0.29 3.7 1.8 51 1.8 Bad -1.2 349.4 6 3 113 4 24 -4.7 100 excr (30)(61) 
Amsacrine 301 27.39 192 --- 0.85 2.6 28 3.8 99.1 2.1 Good 4.7 393.5 5 2 80 5 28 4.6 68 metab 
(30)
(62) 
Amsalog 182 21.78 44.4 --- 0.58 2.4 20 6.4 98 3.8 Good 4.5 464.5 6 3 109 6 33 4.5 8 metab 
(30)
(63) 
Antipy rine 44.8 3.003 75.6 23 1 1.1 43 0.54 81 0.56 Good 0.2 188.2 2 0 24 1 14 0.2 0 metab 
(30)
(64) 
Aprepitant 70 5.94 31.2 --- 0.88 3.5 26 6 98 2.6 Moderate 4.8 534.4 6 2 75 8 37 4.8 0 metab 
(30)
(65) 
Artesunate 74900 69.96 528 --- 0.72 1.5 7.5 0.96 93 1 Good 2.9 384.4 8 1 101 5 27 -0.1 99.9 metab 
(30)
(66) 
Atenolol 175 22.77 52.8 37.5 0.72 0.54 7.7 2.6 29 1.3 Good -0.1 266.3 4 3 85 8 19 -2.1 99.1 excr (30)(67) 
Atomoxetine 651 11.88 88.8 --- 0.99 2.1 32 0.92 95 0.97 Good 3.9 255.4 2 1 21 6 19 1.4 99.8 metab 
(30)
(68) 
Atropine 532 17.49 --- 205 0.99 1.4 31 1.2 61 0.85 Good 1.3 289.4 4 1 50 5 21 -1.2 99.7 both (30)(69) 
Azelastine 630 19.14 600 --- 0.99 3 31 3.3 96 0.95 Good 4 381.9 3 0 36 3 27 2.1 98 metab 
(30)
(70) 
Azithromyci
n 700 11.22 72 --- 0.01 3.7 4.3 4.6 89 4.3 Bad 2.6 749 14 5 180 7 52 0.7 99.1 
meta
b 
(30)
(71) 
Aztreonam 105 4.95 112.8 --- 0.12 0.17 3.1 3.9 79 2.2 Bad 0.3 435.4 11 4 202 7 28 -4.5 100 excr (30)(72) 
Betamipron 644 5.61 96 39.5 0.98 0.34 14 0.68 40 0.59 Good 0.7 193.2 3 2 66 4 14 -2.4 99.9 excr (30)(73) 
Betaxolol 238 50.82 240 --- 0.68 1.7 19 2.8 79 1.2 Moderate 2.3 307.4 4 2 51 11 22 0.3 99.1 metab 
(30)
(74) 
Biapenem 175 4.29 56.4 27.5 0.02 0.7 6.3 1.7 44 1.9 Bad -6.3 351.4 6 2 100 4 24 -5.7 100 excr (30)(75) 
Biperiden 840 22.44 324 --- 1 3.5 28 0.97 95 0.95 Good 4.9 311.5 2 1 23 5 23 2.8 99.3 metab 
(30)
(76) 
Bisoprolol 259 4.29 94.8 60 0.64 1.6 20 2.8 74 1.5 Moderate 1.8 325.4 5 2 60 12 23 -0.2 99.1 both (30)(77) 
brl-42715 840 45.62 252 110 0.38 0.023 9.7 0.81 30 0.77 Good -0.7 266.3 6 1 88 2 18 -4.4 100 excr 
(31)
(25
1) 
Brotizolam 140 7.59 132 65 1 3.8 24 0.61 99.5 0.49 Good 2.7 393.7 3 0 43 1 22 2.7 0 metab 
(30)
(78) 
Bupiv acaine 301 25.08 384 50 0.9 2.2 35 1.4 92 0.92 Good 3.7 288.4 2 1 32 5 21 3.1 90 metab 
(30)
(79) 
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Busulphan 168 1.65 231 --- 1 1.5 15 0.66 49 0.77 Good -0.2 262.4 6 0 78 7 14 -0.2 0 metab 
(30)
(80) 
Butorphanol 2870 30.096 696 --- 0.99 2.6 20 1.2 95 1.1 Good 3.7 327.5 3 2 44 2 24 3 79 metab 
(30)
(81) 
Caf feine 98 4.125 --- 15.3 1 -0.1 38 0.57 30 0.57 Good 0 194.2 3 0 58 0 14 0 0 metab 
(30)
(82) 
Candoxatrila
t 161 4.95 69.6 --- 0.56 0.83 4.5 2.1 62 1 Moderate 0.6 399.5 7 3 122 11 28 -4.1 100 excr 
(30)
(83) 
Captopril 840 4.29 120.96 94.6 0.83 -0.28 11 0.62 32 0.71 Good 0.9 217.3 4 2 58 3 14 -2.6 100 
meta
b 
(30)
(84) 
Carboplatin 105 3.795 39.6 364.5 0.83 -0.28 11 0.62 32 0.71 Good 0.9 217.3 4 2 58 3 14 -2.6 100 excr (30)(85) 
Carmustine 
(BCNU) 5460 --- 213.6 105 1 -0.16 29 0.58 71 0.58 Good 1.3 214.1 3 1 62 5 12 1.3 0 excr 
(30)
(86) 
Carumonam 105 7.26 66 22.5 0.07 0.39 2.8 4.8 74 4.4 Bad -1.2 466.4 13 5 254 10 30 -6.1 100 excr (30)(87) 
Caspof ungin 9.8 0.1419 --- 1.5 0.06 2.5 3.2 13 78 13 Bad -2.9 1093.3 18 16 412 23 77 -6.7 100 
meta
b 
(30)
(88) 
Cef azolin 62.3 1.782 42 9.5 0.01 0.22 3.2 6.4 79 3.4 Bad -1.2 454.5 11 2 156 7 29 -4.9 100 excr (30)(89) 
cef clidin 105 2.93 43.2 17 0.02 0.73 2.6 9.3 76 7.2 Bad -4.5 551.6 11 4 203 8 37 -4 100 excr 
(31)
(25
2) 
Cef epime 154 3.63 26.4 8 0 0.77 2.7 6.6 65 5.4 Bad -3.1 481.6 9 3 147 7 32 -2.5 100 excr (30)(90) 
Cef ixime 70 1.98 4.8 --- 0 -0.13 2.8 4.2 74 2.8 Bad 0.3 453.5 11 4 185 8 30 -4.5 100 excr (30)(91) 
Cefmenoxim
e 255.5 2.4618 
106.9
2 --- 0 0.45 2.8 8.6 87 3.9 Bad 0.3 511.6 13 3 191 8 33 -3.5 100 excr 
(30)
(92) 
Cef metazole 105 8.349 96 16.5 0.03 0.36 3.5 5.2 83 2.1 Bad -1.3 471.5 12 2 163 9 30 -5.1 100 excr (30)(93) 
Cef odizime 42.7 0.363 49.2 6 0 0.7 2.8 8.7 91 4.2 Bad 1.1 584.7 13 4 197 10 37 -3.7 100 excr (30)(94) 
Cefoperazo
ne 91 7.59 69.6 4.8 0 0.86 2.6 11 83 8.2 Bad -0.2 645.7 13 4 220 9 44 -3.9 100 excr 
(30)
(95) 
Cef oranide 46.2 1.782 78 --- 0 0.34 2 11 82 5.9 Bad -3.4 519.6 12 4 194 10 35 -6.9 100 excr (30)(96) 
Cef oselis 123.9 3.168 42 9.5 0.02 0.73 2.3 9.3 70 4.8 Bad -0.3 522.6 12 5 198 9 35 -2.8 100 excr (30)(97) 
Cef otetan 29.4 4.2174 48 8.5 0.05 0.73 3.4 8.4 88 4.8 Bad -1.5 575.6 15 4 220 9 36 -6.3 100 excr (30)(98) 
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Cef ozopran 147 3.102 36 9.5 0 0.48 2.8 12 79 5.5 Bad -3.7 516.5 11 3 181 7 35 -3.2 100 excr (30)(99) 
Cef pimizole 119 --- 7.2 15 0.04 1.1 2.7 14 83 11 Bad -6.9 671.7 12 6 240 12 46 -7.3 100 excr (30)(93) 
Cef piramide 33.6 3.135 68.4 2.5 0.01 0.86 2.4 7.7 91 8.5 Bad 1.9 612.6 13 5 213 9 42 -1.6 100 excr 
(30)
(10
0) 
Cef pirome 133 3.135 38.4 12 0.01 0.66 2.3 9.4 84 6.1 Bad -2.6 515.6 9 3 151 7 35 -2.1 100 excr 
(30)
(10
1) 
Cef tazidime 168 2.871 38.4 10.5 0 0.68 2.6 9.4 88 5.5 Bad -3.8 547.6 11 4 188 9 37 -4.2 100 excr 
(30)
(10
2) 
Cef tizoxime 147 6.3789 39 29.65 0.01 0.25 2.4 2.7 68 1.8 Moderate 0.3 383.4 9 3 147 5 25 -3.4 100 excr 
(30)
(10
3) 
Cef triaxone 18.2 6.6 47.4 0.95 0 0.3 3.1 11 85 8.5 Bad 0 554.6 14 4 209 8 36 -3.9 100 excr 
(30)
(10
4) 
Cicaprost 266 16.17 --- 71.5 0.63 1.8 10 1.9 94 0.97 Good 2.2 374.5 5 3 87 10 27 -1.3 100 excr 
(30)
(10
5) 
Cidof ovir 175 0.231 --- 17.5 0.81 -0.28 3 0.91 19 1.1 Bad -2.4 279.2 8 4 155 6 18 -6.3 --- excr 
(30)
(10
6) 
Ciprofloxaci
n 581 8.91 216 23.5 0.13 -0.41 3.8 3.3 54 2.6 Good -0.2 331.3 6 2 73 3 24 -2.2 100 excr 
(30)
(10
7) 
Citalopram 301 27.06 168 200 0.99 3.3 36 1 93 0.66 Good 3.1 324.4 3 0 36 5 24 1 99.3 metab 
(30)
(10
8) 
Clazosentan 735 3.861 34.68 95 0.4 1.9 4.5 7.1 99 4.1 Bad 2.4 577.6 13 3 200 11 41 -0.6 100 excr 
(30)
(10
9) 
Clev idipine 9940 106.92 1956 --- 0.42 2.7 28 4.6 98 2.3 Moderate 5.5 456.3 7 1 91 10 30 5.5 0 metab 
(30)
(11
0) 
Clindamycin 315 13.2 73.2 --- 0.05 2 6.2 2.6 60 1.6 Moderate 2.6 425 7 4 102 7 27 1.5 96 metab 
(30)
(11
1) 
Clonazepam 61.6 23.265 288 71.5 0.99 1.9 34 1.6 97 0.79 Good 2.4 315.7 4 1 87 2 22 2.4 0 metab 
(30)
(11
2) 
Cocaine 2240 83.49 584.4 --- 0.95 1.6 31 1 75 0.78 Good 2.6 303.4 5 0 56 5 22 1 97 metab 
(30)
(11
3) 
coumarin 1190 6.66 264 170 0.99 1.5 36 0.53 84 0.51 Good 1.4 146.1 2 0 26 0 11 1.4 0 metab 
(31)
(25
3) 
cyclophosph
amide 182 4 240 100 1 1.3 27 0.53 65 0.59 Good 0.8 261.1 2 1 51 5 14 0.8 0 
meta
b 
(31)
(25
4) 
Cyclosporin
e 525 0.561 97.2 --- 0.02 3.7 3 13 96 7.7 Bad 14.4 
1202.
6 12 5 279 15 85 14.4 0 
meta
b 
(30)
(11
4) 
Darif enacin 840 19.47 468 --- 0.98 4.4 26 2.4 97 1.2 Good 3.6 426.6 3 1 56 7 32 1.8 99 metab 
(30)
(11
5) 
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Decitabine 9100 2.607 103.2 --- 0.91 -0.19 3.4 0.64 24 0.67 Bad -1.9 228.2 7 3 121 2 16 -1.9 0 metab 
(30)
(11
6) 
Dexamethas
one 231 1.056 76.8 --- 1 2 18 2.1 89 2.9 Good 1.8 392.5 5 3 95 2 28 1.8 0 
meta
b 
(30)
(11
7) 
Dexloxiglum
ide 259 1.9833 368.4 --- 0.67 1.2 15 3.9 97 1.3 Bad 4.3 461.4 5 2 96 14 30 1.5 99.9 
meta
b 
(30)
(11
8) 
Diclof enac 245 5.544 16.8 42.5 0.94 1.3 23 0.81 99 0.67 Good 4.7 296.2 3 2 49 4 19 1.6 99.9 metab 
(30)
(11
9) 
Didanosine 770 49.665 303.6 136 0.95 
-
0.03
7 
19 0.76 26 0.68 Good -0.3 236.2 6 2 93 2 17 -2.8 100 both 
(30)
(12
0) 
Dif lomoteca
n 589.4 7.59 258 --- 0.73 2.5 32 5.1 95 2.5 Good 0.9 412.4 5 1 80 1 30 0.9 0 
meta
b 
(30)
(12
1) 
disopyramid
e 168 11.32 348 95 0.91 1.2 32 1.3 87 0.98 Good 2.6 339.5 3 1 59 8 25 0.1 99.8 both 
(31)
(25
5) 
Dof etilide 364 21.945 122.4 --- 0.81 1.7 14 4.6 75 2.6 Moderate 2 441.6 6 2 105 11 29 1.1 88 both 
(30)
(12
2) 
Dolasetron 12600 23.76 324 385 0.94 1.5 27 2.6 85 1.3 Good 2.3 324.4 4 1 62 3 24 2.3 6 metab 
(30)
(12
3) 
dopa (l) 1610 36.3 228 85 0.83 -0.15 3.6 0.8 20 1.2 Bad -2.8 197.2 5 4 104 3 14 -5.3 100 metab 
(31)
(25
6) 
Doripenem 228.2 11.781 56.4 38.5 0.11 0.75 2.7 4.8 66 3.3 Bad -3.8 420.5 8 5 162 7 27 -6.3 100 excr 
(30)
(12
4) 
Doxazosin 112 9.9 156 --- 0.88 2.1 29 5.4 95 2.4 Moderate 4 451.5 9 1 112 4 33 4 10 metab 
(30)
(12
5) 
doxorubicin 1190 11.32 204 140 0 1.9 3.3 7.5 57 6.3 Bad 0.3 543.5 12 6 206 5 39 -1.4 100 both 
(31)
(25
7) 
Enprof ylline 280 3.96 28.8 --- 0.93 -0.97 14 0.68 18 0.57 Good 0.7 166.2 3 2 61 1 12 0.7 0 excr 
(30)
(12
6) 
Eptaloprost 4634 56.1 --- 315.5 0.64 1.9 9.4 2 96 1.2 Moderate 2.6 402.5 5 3 87 12 29 -0.1 99.8 metab 
(30)
(12
7) 
Eritoran 0.91 0.0825 0.228 --- 0.26 3.5 6.5 5.9 99.1 8 Bad 19.1 
1311.
7 18 7 304 59 89 13.7 100 
meta
b 
(30)
(12
8) 
Ertapenem 31.5 3.3 --- 2.35 0.11 0.62 1.7 9.4 65 4.5 Bad -1.8 475.5 9 5 156 7 33 -5.9 100 excr 
(30)
(12
9) 
Ery thromyci
n 392 24.09 228 158 0 3.6 4 5.5 88 4.8 Bad 1.6 733.9 14 5 194 7 51 0.9 85 
meta
b 
(30)
(13
0) 
Ethinylestra
diol 490 18.15 --- 180 0.58 3.3 29 0.97 99 0.69 Good 3.9 296.4 2 2 40 0 22 3.9 0 
meta
b 
(30)
(13
1) 
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ethosuximid
e 10.5 1.03 5.04 1.65 1 -0.32 28 0.61 28 0.59 Good 0.4 141.2 2 1 46 1 10 0.4 0 
meta
b 
(31)
(19
6) 
Etomidate 910 30.69 204 --- 1 2.3 46 0.52 94 0.48 Good 2.4 244.3 3 0 44 5 18 2.4 0 excr 
(30)
(13
2) 
Etoposide 35 7.59 156 7.5 0.04 2.6 8.7 7.1 87 3.5 Bad 0 588.6 13 3 161 5 42 0 0 both 
(30)
(13
3) 
Famotidine 462 7.26 103.2 75 0.89 0.79 6.3 2 54 1.6 Bad -0.6 337.5 9 4 176 7 20 -1.2 77 excr 
(30)
(13
4) 
Felodipine 770 20.13 396 --- 0.23 3.4 34 2.2 98 1.5 Moderate 5.3 384.3 5 1 65 6 25 5.3 0 metab 
(30)
(13
5) 
Fentany l 329 19.14 648 --- 1 3.5 34 1 95 0.88 Good 3.6 336.5 2 0 24 6 25 2.5 96 metab 
(30)
(13
6) 
Flecainide 343 11.22 288 --- 0.91 1.8 31 13 45 3.1 Good 3.7 414.3 4 2 60 9 28 1.5 99.5 metab 
(30)
(13
7) 
Fleroxacin 168 1.914 19.2 20 0.11 0.35 13 3.5 42 1.5 Good 0.2 369.3 6 1 64 4 26 -2 --- excr 
(30)
(13
8) 
f lomoxef 420 6.33 60 40 0.06 0.82 3.3 6 82 2.2 Bad -1.2 496.5 12 3 169 11 32 -4.8 100 excr 
(31)
(25
8) 
Fluconazole 21.7 1.386 7.8 --- 1 1.4 26 0.8 83 0.68 Good -0.4 306.3 5 1 82 5 22 -0.4 0 excr 
(30)
(13
9) 
Flumazenil 1120 48.51 192 --- 0.99 1.5 45 0.8 84 0.61 Good 1.3 303.3 4 0 64 3 22 1.3 0 metab 
(30)
(14
0) 
f lunisolide 840 2.93 154.8 95 1 1.9 36 4.5 96 1.3 Good 2.4 434.5 6 2 93 2 31 2.4 0 metab 
(31)
(25
9) 
Flunitrazepa
m 98 26.4 936 --- 0.98 2.3 36 1.2 96 0.7 Good 1.8 313.3 4 0 78 2 23 1.8 0 
meta
b 
(30)
(14
1) 
f luv astatin 1120 10.66 60 175 0.87 2.1 9.7 2.6 98 1.5 Good 4 411.5 4 3 83 8 30 0.9 99.9 metab 
(31)
(26
0) 
Furosemide 112 2.31 235.2 17 0.84 0.33 5 1.7 90 0.94 Good 1.9 330.7 5 3 123 5 21 -1.2 100 excr 
(30)
(14
2) 
Gabapentin 119 3.003 --- 11.5 0.51 1.7 4.9 2.3 73 1.3 Moderate 1 382.4 6 4 115 13 26 -1.7 99.8 excr 
(30)
(14
3) 
Galanthami
ne 392 10.461 147.6 --- 0.97 1.5 36 0.78 72 0.8 Good 1 287.4 4 1 42 1 21 0.4 77 
meta
b 
(30)
(14
3) 
Garenoxaci
n 86.1 3.993 29.16 16.95 0.46 1.4 4.3 4.9 94 2.3 Good 0.7 426.4 6 2 79 5 31 -1.5 100 excr 
(30)
(14
4) 
Gatif loxacin 196 6.369 50.4 51 0.11 -0.23 3.2 4.2 55 2.9 Good 0.2 375.4 7 2 82 4 27 -2.1 100 excr 
(30)
(14
5) 
Gav estinel 6.23 0.396 25.2 22 0.67 1.2 15 1.4 99 0.86 Moderate 5.2 375.2 3 3 82 4 25 2.1 100 metab 
(30) 
(14
6) 
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Gemcitabine 2240 1.65 129.12 885 0.92 1.3 5.4 0.68 23 0.6 Good -0.7 263.2 6 3 108 2 18 -0.7 0 
meta
b 
(30)
(14
7) 
Gentamicin 70 2.574 25.2 --- 0 1.8 2.6 2.7 33 2.5 Bad -2.4 449.5 12 8 214 6 31 -8.1 100 excr 
(30)
(14
8) 
Haloperidol 546 28.446 --- 39 1 2.8 33 2.9 96 1.2 Good 3.8 375.9 3 1 41 6 26 2.7 92 metab 
(30)
(14
9) 
hi-6 224 3.26 44.4 43 0.89 0.6 21 1.8 61 0.96 Bad -7.2 288.3 4 2 93 6 21 -7 100 excr 
(31)
(26
1) 
Hy droxystau
rosporine, 7- 0.259 21.45 122.4 --- 0.54 2.9 16 7 96 4.1 Good 3.4 482.5 5 3 90 2 36 2.1 95 
meta
b 
(30)
(15
0) 
Ibuprof en 57.4 1.584 5.88 --- 0.97 0.47 19 0.63 97 0.66 Good 3.7 206.3 2 1 37 4 15 0.8 99.9 metab 
(30)
(15
1) 
If etroban 448 28.875 --- 95.5 0.68 1.4 12 4.4 92 1.3 Moderate 3.4 440.5 5 2 102 11 32 0.7 99.8 metab 
(30)
(15
2) 
Iloprost 1120 10.692 806.4 --- 0.66 1.9 9.1 1.3 95 0.94 Good 2.7 360.5 4 3 78 9 26 0.1 99.8 metab 
(30)
(15
3) 
Imatinib 231 6.567 468 60 0.68 1.9 14 5.9 97 5 Good 4.5 493.6 7 2 86 7 37 3.9 70 metab 
(30)
(15
4) 
Imipenem 210 4.785 51.6 28.5 0.1 1.9 3.8 3 19 2.9 Bad -1.4 299.4 6 4 114 7 20 -3.9 100 metab 
(30)
(15
5) 
Indinav ir 1260 29.37 180 178.5 0.11 2.5 3 12 62 8.6 Bad 3.7 613.8 7 4 118 12 45 3.6 14 metab 
(30)
(15
6) 
indomethaci
n 140 0.14 0.024 65 0.85 1.5 25 1.2 98 0.76 Good 4.1 356.8 4 1 64 5 25 1.1 99.9 both 
(31)
(26
2) 
Inogatran 427 27.39 108 130 0 1.5 2.9 7.1 94 5.7 Bad 1.9 653.4 11 5 186 5 39 0.4 --- excr 
(30)
(15
7) 
Iododoxorub
icin 9800 12.078 78 216.5 0.43 0.08 2.5 6 56 5.3 Bad -0.1 438.6 6 6 161 12 31 -3.4 100 
meta
b 
(30)
(15
8) 
Iomeprol 98 2.442 40.8 --- 0.4 1.1 2.8 6.2 73 2.3 Bad -2.3 777.1 8 7 180 10 31 -2.3 0 excr 
(30)
(15
9) 
Ipratropium 2198 29.7 499.2 --- 0.68 2.1 34 1.5 93 1.1 Bad -2.2 332.5 3 1 47 6 24 -2.2 100 both 
(30)
(16
0) 
Irinotecan 490 18.381 46.8 66.5 0.53 2.8 18 9.8 94 7.4 Moderate 2.7 586.7 8 1 113 5 43 1.1 99 metab 
(30)
(16
1) 
Isosorbide 
Dinitrate 2170 40.26 --- 294 0.89 1.7 11 0.66 60 0.65 Bad -3.5 236.1 8 0 129 4 16 -3.5 0 
meta
b 
(30)
(16
2) 
Ketamine 1330 37.851 386.4 --- 0.97 1.8 46 0.49 69 0.51 Good 2.9 237.7 2 1 29 2 16 2.9 10 metab 
(30)
(16
3) 
Ketanserin 469 1.254 296.4 --- 0.98 2 30 3.9 93 2 Good 3 395.4 4 1 70 5 29 2.6 60 metab 
(30)
(16
4) 
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ketorolac 24.5 1.2 15.6 3 0.8 0.21 17 0.71 88 0.64 Good 1.6 255.3 3 1 59 3 19 -1.4 99.9 both 
(31)
(26
3) 
L-692429 213.5 0.891 231.6 28.5 0.46 1.9 2.1 10 98 8.4 Moderate 4.1 567.7 7 4 136 10 42 1.6 100 metab 
(30)
(16
5) 
Lamif iban 133 3.135 84 13 0.5 1 2.9 7.5 69 4.9 Bad -0.6 468.5 7 5 166 9 34 -3.1 100 excr 
(30)
(16
6) 
lamiv udine 1400 23.98 264 65 0.81 0.36 14 0.6 24 0.56 Bad -1.5 229.3 6 2 88 2 15 -1.5 0 excr 
(31)
(26
4) 
latamoxef 84 3.13 26.4 10 0.06 0.49 2.6 7.3 81 4 Bad -0.8 520.5 13 4 206 9 36 -5.6 100 excr 
(31)
(26
5) 
Lidocaine 1120 15.411 --- 330 0.42 2.3 35 0.94 78 0.74 Good 2 234.3 2 1 32 5 17 1.2 93 metab 
(30)
(16
7) 
Lubeluzole 119 8.25 499.2 --- 0.91 2.5 32 4.1 95 1.6 Good 4.3 433.5 5 1 49 7 30 4.1 41 metab 
(30)
(16
8) 
Marav iroc 658 24.42 252 --- 0.67 3.6 26 7 99.1 5.3 Moderate 3.3 513.7 4 1 63 8 37 0.7 99.9 metab 
(30)
(16
9) 
Maxipost 1050 14.19 42 --- 0.99 4 35 0.6 99.2 0.5 Good 4.1 359.7 2 0 30 3 24 4.1 0 metab 
(30)
(17
0) 
Melagatran 133 5.577 84 --- 0.39 1.1 2 6.5 46 5.7 Bad -0.8 429.5 6 5 149 9 31 -3.7 100 excr 
(30)
(17
1) 
Meloxicam 8.4 0.0825 2.04 --- 0.49 1.2 24 1.2 85 0.81 Good 2.3 351.4 5 2 100 2 23 -0.6 99.9 metab 
(30)
(17
2) 
MEN-10755 175 3.564 219.6 --- 0.02 2 2.5 9.3 65 9.2 Bad 0.1 642.7 14 7 241 6 46 -2.3 100 metab 
(30)
(17
3) 
meperidine 1190 84.25 516 5 1 2 41 0.7 82 0.58 Good 2.2 247.3 3 0 30 4 18 1.2 92 metab 
(31)
(26
6) 
Meropenem 273 8.712 48 37.5 0.04 0.75 3.1 3.7 52 3 Bad -3.3 383.5 7 3 110 5 26 -6 100 excr 
(30)
(17
4) 
methotrexat
e 175 4 14.4 40 0.2 0.19 2 7 74 3.2 Bad -0.5 454.4 12 5 211 9 33 -5.2 100 
meta
b 
(31)
(26
7) 
Metoclopra
mide 399 15.84 277.2 --- 0.99 1.4 25 2 56 1.2 Good 2.2 299.8 4 2 68 7 20 0 99.4 both 
(30)
(17
5) 
Metoprolol 910 28.776 393.6 109.5 0.7 1 23 2 74 1.1 Good 1.5 267.4 4 2 51 9 19 -0.6 99.1 metab 
(30)
(17
6) 
Metronidazo
le 59.5 1.914 30 --- 0.99 0.31 21 0.6 45 0.62 Good -0.5 171.2 4 1 84 3 12 -0.5 0 both 
(30)
(17
5) 
Micaf ungin 11.9 0.33 9.36 --- 0.08 2.5 5.2 8.8 88 9.4 Bad -2.6 1270.3 23 16 510 18 89 -6.1 100 
meta
b 
(30)
(17
7) 
Midazolam 371 29.7 422.4 111.5 1 3.6 42 0.58 99 0.48 Good 3.4 325.8 2 0 30 1 23 3.4 1 metab 
(30)
(17
8) 
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Mivacurium 
(cis/cis) 364 3.267 41.64 --- 0.43 4.9 5.1 8.9 99 5.6 Bad 2.6 
1029.
3 14 0 145 30 74 2.6 100 
meta
b 
(30)
(17
9) 
mk-571 64.4 12.32 48 9.5 0.54 2.1 21 3.7 99.8 1.5 Moderate 5.7 515.1 6 1 71 11 34 2.6 99.9 metab 
(31)
(26
8) 
Morphine 1820 19.107 733.2 227 0.99 1.3 14 0.84 34 0.84 Good 0.6 285.3 4 2 53 0 21 -0.3 88 metab 
(30)
(18
0) 
Moxalactam 50.4 3.003 26.4 11.5 0.06 0.49 2.6 7.3 81 4 Bad -0.8 520.5 13 4 206 9 36 -5.6 100 excr 
(30)
(18
1) 
moxestrol 23.8 17.32 62.4 16 0.72 3.3 32 1 98 0.71 Good 2.6 326.4 3 2 50 1 24 2.6 0 metab 
(31)
(26
9) 
Moxif loxacin 168 14.025 44.4 57.5 0.18 0.51 3.3 4.9 67 4.2 Good 0.5 401.4 7 2 82 4 29 -2.1 100 metab 
(30)
(18
2) 
naltrexone 3360 26.64 1080 330 1 1.6 15 2.3 45 1.8 Good 0.4 341.4 5 2 70 2 25 -0.1 56 metab 
(31)
(27
0) 
naproxen 4.9 0.14 0.48 3.05 0.85 0.49 22 0.61 96 0.62 Good 2.8 230.3 3 1 47 3 17 0.3 99.7 metab 
(31)
(27
1) 
Napsagatra
n 448 21.582 313.2 96 0.34 0.94 2.3 11 67 7.3 Bad 1.3 558.7 7 5 186 12 39 -1.2 100 excr 
(30)
(18
3) 
Nicardipine 770 53.79 444 135 0.15 3.5 16 5 89 4.2 Moderate 5.2 479.5 8 1 114 11 35 5 44 metab 
(30)
(18
4) 
nicardipine 490 38.3 576 135 0.15 3.5 16 5 89 4.2 Moderate 5.2 479.5 8 1 114 11 35 5 44 metab 
(31)
(27
2) 
Nimodipine 1050 6.468 216 165 0.19 2.8 23 4 90 2.6 Good 4 418.4 8 1 120 10 30 4 0 metab 
(30)
(18
5) 
Nisoldipine 1050 15.114 446.4 --- 0.23 3.9 25 4.5 90 2.2 Good 4.6 388.4 7 1 110 8 28 4.6 0 metab 
(30)
(18
6) 
Of loxacin 175 4.356 278.4 --- 0.17 0.13 11 3.1 47 1.8 Good 0 361.4 7 1 73 2 26 -2.2 100 excr 
(30)
(18
7) 
Oleandomyc
in 637 16.83 144 --- 0.01 3.5 4.5 4.6 93 4.6 Bad 1.6 687.9 13 3 166 6 48 0.8 85 
meta
b 
(30)
(18
8) 
Oseltamivir 
acid 336 8.25 63.6 --- 0.69 0.35 2.7 1.3 53 1.8 Bad -1.2 284.4 5 3 102 6 20 -3.7 100 
meta
b 
(30)
(18
9) 
Paclitaxel 448 3.531 --- 31 0.07 3.6 7.5 7.6 97 8.5 Bad 4.7 853.9 14 4 221 14 62 4.7 0 metab 
(30)
(19
0) 
Panipenem 182 9.141 58.2 32.6 0.03 0.99 4.7 2.4 40 2.1 Bad -1.8 339.4 6 3 105 5 23 -4.3 100 excr 
(30)
(19
1) 
Pef loxacin 140 9.3951 94.68 55.15 0.19 
-
0.08
5 
14 1.9 49 1.4 Good 0.2 333.4 6 1 64 3 24 -2 --- both 
(30)
(19
1) 
41 
 
Compound 
Name 
human 
CL 
(mL/mi
n) 
rat CL 
(mL/mi
n) 
dog 
CL(m
L/min
)  
monkey 
CL 
(mL/min) 
CNSa 
 (0-1) 
Elog
D 
Papp 
(10^-6 
cm/sec
) 
PGPr 
(BA:AB 
ratio) 
PPB 
(0-
100%) 
PGPh 
(BA:AB 
ratio) 
OrlA ClogP 
MW 
(Da) 
HB
A 
HB
D 
PSA 
(Å2)  RCB 
non
H 
Clog
D  
%IONI 
(0-
100%) 
ELI
M Ref 
pelrinone 280 9.32 132 65 0.91 0.46 31 0.9 55 0.71 Good -0.7 241.3 6 2 90 3 18 -0.9 41 excr 
(31)
(27
3) 
Pentamidine 5180 36.795 727.2 --- 0.95 2.6 7.9 2 85 1.2 Moderate 2.3 340.4 4 4 118 10 25 -0.7 100 metab 
(30)
(19
2) 
Pentobarbit
al 32.9 2.772 15.6 --- 1 0.77 30 0.96 73 0.84 Good 2.1 226.3 3 2 75 4 16 1.9 33 
meta
b 
(30)
(19
3) 
Pentoxifyllin
e 2730 2.4024 444 --- 0.97 0.6 42 1 64 0.93 Good 0.1 278.3 4 0 76 5 20 0.1 0 
meta
b 
(30)
(19
4) 
Phencyclidin
e 357 21.879 649.2 183 1 3.3 34 0.6 97 0.59 Moderate 5.1 243.4 1 0 3 2 18 4.2 87 
meta
b 
(30)
(19
5) 
Phenobarbit
al 4.41 0.264 1.2 --- 1 1.4 25 0.88 50 0.73 Good 1.4 232.2 3 2 75 2 17 1 55 
meta
b 
(30)
(19
6) 
pheny toin 39.9 2.46 33.6 39.5 0.99 2.1 31 1.1 94 0.61 Good 2.1 252.3 2 2 58 2 19 2.1 11 metab 
(31)
(27
4) 
Pindolol 539 15.939 1070.4 --- 0.54 0.57 23 1.1 45 1.1 Good 1.7 248.3 3 3 57 6 18 -0.4 99.2 both 
(30)
(19
7) 
Piperacillin 280 5.841 79.2 36 0 1.3 2.4 8.8 63 8.1 Moderate 1.7 517.6 8 3 156 6 36 -2 100 excr 
(30)
(19
8) 
Pirmenol 126 20.46 99.6 24.6 0.92 3 27 1 96 0.96 Good 3.4 338.5 3 1 36 6 25 0.9 99.8 both 
(30)
(19
9) 
Prazosin 329 22.704 169.2 --- 0.94 1.9 39 4 91 1.6 Good 2.5 383.4 7 1 107 4 28 2.5 10 metab 
(30)
(20
0) 
Prednisone 175 51.051 298.8 49 1 1.6 23 2.3 86 1.9 Good 1.7 358.4 5 2 92 2 26 1.7 0 metab 
(30)
(20
1) 
Procainamid
e 700 39.6 104.4 --- 0.99 0.45 16 1.6 15 1.1 Good 1.4 235.3 3 2 58 6 17 -0.9 99.7 excr 
(30)
(20
2) 
Propaf enon
e 1120 9.273 334.8 --- 0.31 2 32 4.6 85 1.9 Moderate 3.6 341.4 4 2 59 11 25 2.2 94 
meta
b 
(30)
(20
3) 
Propof ol 2520 35.409 477.6 --- 0.97 2.7 37 0.51 96 0.5 Good 3.9 178.3 1 1 20 2 13 3.9 0 metab 
(30)
(20
4) 
Propranolol 840 31.119 621.6 104 0.39 1.6 35 1.1 85 1 Good 2.8 259.3 3 2 41 6 19 0.7 99.1 metab 
(30)
(20
5) 
Quinidine 280 6.1479 42.96 112 0.59 1.4 35 0.97 87 0.99 Good 2.8 324.4 4 1 46 4 24 0.9 99 metab 
(30)
(20
6) 
Quinine 133 29.014 97.32 --- 0.59 1.4 35 0.97 87 0.99 Good 2.8 324.4 4 1 46 4 24 0.9 99 metab 
(30)
(20
7) 
Rabeprazol
e 280 27.192 1032 --- 0.85 1.9 40 2.7 94 1 Good 2.1 359.4 5 1 77 8 25 2.1 3 
meta
b 
(30)
(20
8) 
Ranitidine 672 10.527 139.2 --- 0.8 1.6 16 2.1 56 1.6 Good 0.7 314.4 6 2 86 10 21 -0.4 91 excr 
(30)
(20
9) 
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Recainam 315 27.06 156 133.5 0.88 1.1 27 2.3 82 1.9 Good 1.9 263.4 2 3 53 6 19 -0.8 99.9 excr 
(30)
(21
0) 
Remikiren 812 39.27 296.4 100 0.22 3 1.5 10 92 6.3 Bad 3.6 630.8 7 5 161 16 44 3.4 17 metab 
(30)
(21
1) 
Remoxipride 119 56.1 58.8 --- 0.99 1.4 36 1.3 79 1 Good 3.3 371.3 4 1 51 6 22 1.4 97 metab 
(30)
(21
2) 
Ribav irin 364 14.19 --- 18.5 0.8 -0.6 2.2 0.78 19 0.76 Bad -2.8 244.2 7 4 144 3 17 -2.8 0 metab 
(30)
(21
3) 
Ritipenem  528.5 5.115 88.8 23.25 0.46 1.3 6.9 2.4 57 1.6 Moderate -0.8 360.3 9 2 145 9 24 -0.8 0 metab 
(30)
(21
4) 
ro 25-6833 26.6 0.32 32.4 3.9 0.06 0.93 3.1 11 89 5.2 Bad -1.1 546.5 10 4 179 7 36 -5.3 --- both 
(31)
(27
5) 
Ro25-6833 26.6 0.3135 32.4 3.85 0.06 0.93 3.1 11 90 5.2 Bad -1.1 546.5 10 4 179 7 36 -5.3 --- both 
(30)
(21
5) 
Romidepsin 518 206.25 --- 139.5 0.39 2.5 7 12 93 3.5 Moderate 3.4 540.7 8 4 143 2 36 3.4 0 metab 
(30)
(21
6) 
Sch34343 525 7.524 106.8 33.5 0.1 0.58 2.9 2.1 57 1.3 Bad -1 334.4 8 3 130 7 21 -4.3 100 both 
(30)
(21
7) 
Sematilide 259 8.448 108 --- 0.93 0.6 20 2.3 36 1.6 Good 1.4 313.4 4 2 79 8 21 -0.9 100 excr 
(30)
(21
7) 
Semaxanib 980 14.85 624 138.5 0.95 1.6 46 0.69 92 0.55 Good 2.8 238.3 1 2 45 1 18 2.8 0 metab 
(30)
(21
8) 
Sildenaf il 637 15.84 144 --- 0.76 2.4 33 7.2 91 6.4 Good 2 474.6 7 1 109 7 33 2 4 metab 
(30)
(21
9) 
Sinitrodil 2071.3 28.017 764.4 131.5 0.98 1.4 37 0.68 63 0.58 Good -0.8 238.2 5 0 85 4 17 -0.8 0 metab 
(30)
(22
0) 
Sitagliptin 420 14.85 109.2 --- 0.94 2.3 22 2.4 85 2.8 Good 0.7 407.3 4 1 77 5 28 0.6 39 excr 
(30)
(22
1) 
Sparf osic_A
cid 85.4 5.742 49.2 11.5 0.63 0.74 2.3 0.95 27 0.74 Bad -2.2 255.1 8 5 171 6 16 -8.4 100 
meta
b 
(30)
(22
2) 
Stav udine 574 6.666 --- 47 0.86 0.13 14 0.68 24 0.64 Good -0.5 224.2 4 2 79 2 16 -0.5 2 excr 
(30)
(22
3) 
sudoxicam 7 0.06 0.48 0.95 0.53 0.94 19 0.91 88 0.71 Good 1.8 337.4 5 2 100 2 22 -1.1 99.9 metab 
(31)
(27
6) 
Sulf adiazine 38.5 0.363 --- 3.2 0.96 0.13 11 0.88 87 0.74 Good 0.1 250.3 5 2 98 3 17 -1.2 89 excr 
(30)
(22
4) 
Sulf inpyrazo
ne 23.8 0.1518 10.08 2.25 0.95 3 33 1.4 97 0.9 Good 1.7 404.5 3 0 58 6 29 -0.2 99 excr 
(30)
(22
5) 
Sulf isoxazol
e 21 0.2145 16.56 --- 0.93 -1.2 13 1.1 83 0.85 Good 0.2 267.3 4 2 98 3 18 -1.2 99.7 excr 
(30)
(17
5) 
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Sumatriptan 1330 9.24 166.8 --- 0.95 0.79 21 2.6 49 1.9 Good 0.7 295.4 3 2 65 6 20 -1.1 99.2 both 
(30)
(22
6) 
Susalimod 4.9 20.46 240 9.5 0.63 1.4 6.8 2.5 99 1 Good 4.3 408.4 6 3 117 6 29 0.8 100 excr 
(30)
(20
9) 
Tacrolimus 49 10.428 2784 22 0.02 4 6.9 7.3 98 6 Bad 5.8 804 12 3 178 7 57 5.8 0 metab 
(30)
(22
7) 
Tamsulosin 43.4 27.126 231.6 --- 0.79 2.3 15 5.7 86 3.2 Moderate 2.2 408.5 6 2 100 11 28 0.6 98 metab 
(30)
(22
8) 
Tebuf elone 623 13.646 370.8 74.5 0.95 3.2 25 0.93 99.4 0.63 Moderate 5.8 300.4 2 1 37 6 22 5.8 3 metab 
(30)
(22
9) 
Teicoplanin 
A2-1 14 0.1749 1.2 --- 0.13 1.7 2.9 6.9 95 7.7 Failed --- 
1877.
6 34 24 662 19 132 --- 100 excr 
(30)
(23
0) 
Telav ancin 14 0.2805 13.2 4.75 0.14 1.9 3.7 9.5 97 8.1 Bad 1.9 1755.6 31 23 608 30 121 -1.1 100 excr 
(30)
(19
1) 
Tenof ov ir 217 --- 70.8 81 0.74 0.26 4.2 0.88 26 1 Bad -1.6 287.2 8 3 146 5 19 -5.5 100 excr 
(30)
(23
1) 
Tezosentan 567 1.419 --- 78 0.4 2.1 4.7 6.7 99 3.8 Bad 3.3 605.6 13 3 200 12 43 0.3 100 excr 
(30)
(23
2) 
Theophy llin
e 60.2 0.7425 21.6 19 0.94 -1.4 18 0.91 42 0.72 Good 0 180.2 3 1 69 0 13 -0.1 5 
meta
b 
(30)
(23
3) 
tiazof urine 98 2.3 33.6 17.5 0.75 0.038 2.6 0.84 20 0.71 Bad -1.9 260.3 6 4 126 3 17 -1.9 0 excr 
(31)
(27
7) 
tiludronate 21 1.1 6 4.15 0.77 0.62 4.3 0.71 60 0.7 Moderate 0.3 318.6 7 4 135 4 17 -5.2 100 excr 
(31)
(27
8) 
Tolcapone 133 2.904 22.8 --- 0.34 1.3 25 1.5 99 0.84 Good 3.2 273.2 5 2 103 3 20 1 99.8 metab 
(30)
(23
4) 
Tomopenem 133 5.181 47.52 8.5 0.15 0.63 2.1 9.7 62 6 Bad -3.8 537.6 9 6 192 9 37 -6.8 100 excr 
(30)
(23
5) 
Topotecan 910 11.352 211.2 480.5 0.46 1.6 19 7.3 76 4.6 Good -0.3 423.5 7 2 103 3 31 -0.9 63 both 
(30)
(23
6) 
Torsemide 37.1 1.2342 1.68 --- 0.74 0.96 16 1.6 96 0.97 Good 3.4 348.4 5 3 100 5 24 1.4 100 metab 
(30)
(23
7) 
Tramadol 455 20.955 655.56 --- 0.97 1.1 36 0.78 88 0.81 Good 3.1 263.4 3 1 33 4 19 1.1 99.4 
meta
b 
(30)
(23
8) 
trimethadion
e 49 1.9 34.8 8 0.66 2.6 25 5 99.6 1.8 Moderate 5.6 441.5 6 2 85 5 31 4.5 92 
meta
b 
(31)
(27
9) 
Trimethopri
m 147 13.2 76.8 --- 0.98 1.2 22 9.4 80 2.1 Good 1 290.3 7 2 106 5 21 0.7 41 
meta
d 
(30)
(23
9) 
Trimetrexate 53.9 23.463 398.4 42.5 0.87 2.1 21 3.2 97 1.5 Good 1.8 369.4 8 3 118 6 27 0.4 94 metab 
(30)
(24
0) 
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Compound 
Name 
human 
CL 
(mL/mi
n) 
rat CL 
(mL/mi
n) 
dog 
CL(m
L/min
)  
monkey 
CL 
(mL/min) 
CNSa 
 (0-1) 
Elog
D 
Papp 
(10^-6 
cm/sec
) 
PGPr 
(BA:AB 
ratio) 
PPB 
(0-
100%) 
PGPh 
(BA:AB 
ratio) 
OrlA ClogP 
MW 
(Da) 
HB
A 
HB
D 
PSA 
(Å2)  RCB 
non
H 
Clog
D  
%IONI 
(0-
100%) 
ELI
M Ref 
troglitazone 245 7.33 79.2 41.5 0.66 2.6 25 5 99.6 1.8 Moderate 5.6 441.5 6 2 85 5 31 4.5 92 metab 
(31)
(28
0) 
Trospectom
y cin 119 1.4124 32.28 --- 0.18 1.1 3.3 2.1 31 1.9 Bad -1.3 374.4 9 5 130 5 26 -2.8 97 excr 
(30)
(24
1) 
Trovaf loxaci
n 98 4.455 
109.5
6 29.65 0.4 0.8 4.4 5.8 91 2.2 Good 0.3 416.4 7 2 100 3 30 -1.8 100 both 
(30)
(24
2) 
UK-240455 420 3.96 156 --- 0.8 0.87 12 2.1 83 1.3 Good -0.9 368.2 5 3 116 4 22 -1.1 22 excr 
(30)
(24
3) 
v alproate 7.7 1.4 36 20 1 0.53 13 0.52 81 0.55 Good 2.8 144.2 2 1 37 5 10 0.2 99.7 metab 
(31)
(28
1) 
Valproic Acd 11.2 1.386 36.36 21 1 0.53 13 0.52 81 0.55 Good 2.8 144.2 2 1 37 5 10 0.2 99.7 metab 
(30)
(24
4) 
Venlaf axine 980 21.285 162 205 1 1.5 37 0.72 86 0.85 Good 3.3 277.4 3 1 33 5 20 1.6 99 metab 
(30)
(24
5) 
Verapamil 1260 11.055 321.6 114 0.36 3.5 20 1.5 99 1.7 Moderate 4.5 454.6 6 0 64 13 33 2.9 97 metab 
(30)
(24
6) 
Vildagliptin 693 15.939 260.4 125 0.96 1.8 20 1.4 33 1.2 Good 0.7 303.4 4 2 76 3 22 -0.5 94 metab 
(30)
(24
7) 
v inblastine 840 8.33 264 35 0.01 3.1 5.8 8.8 88 9.1 Bad 5.2 811 12 3 154 10 59 4.7 76 metab 
(31)
(28
2) 
v incristine 126 0.67 117.6 24 0.1 3.5 5.9 9.4 98 9 Bad 8.2 822 10 2 148 10 60 8.2 1 excr 
(31)
(28
3) 
Voriconazol
e 581 3.003 18 --- 0.99 2.1 38 0.73 93 0.6 Good 0.5 349.3 5 1 77 5 25 0.5 0 
meta
b 
(30)
(24
8) 
Vorinostat 1960 42.735 656.4 --- 0.9 0.81 19 1.8 84 1 Good 1 264.3 3 3 78 8 19 1 0 metab 
(30)
(24
9) 
warf arin 2.8 0.12 3.6 0.65 0.83 2.4 31 0.85 97 0.66 Good 2.9 308.3 4 1 64 4 23 0.1 99.9 metab 
(31)
(27
4) 
Zalcitabine 392 3.696 --- 51.5 0.97 0.34 12 0.63 21 0.59 Bad -1.2 211.2 5 2 88 2 15 -1.3 0 excr 
(30)
(25
0) 
zidov udine 1680 15.32 168 75 0.83 0.34 10 1.1 23 1 Moderate -0.6 269.3 6 4 131 3 19 --- --- metab 
(31)
(28
4) 
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Table 2. AS parameter estimation of basic structure model and final model based on the 
Nonlinear MEM approach 
 
  Basic Structure Model Bootstrap   
        95% CI 
Parameter Estimation  RSE% Median LL UL 
AS coefficient 2.06 7.80 2.06 1.73 2.37 
AS exponent 0.629 2.93 0.628 0.59 0.66 
            
Inter-drug variability (IDV)           
ŋ AS coefficient 1.04 29.4 1.03 0.56 1.85 
η AS exponent 0.413 29.1 0.407 0.10 0.29 
Residual error model   
σadd 0.180 --- 0.180 --- --- 
Eta Shrinkage (ŋ - shrinkage)           
AS coefficient 3.43         
AS exponent 2.76         
Epsilon shrinkage (Ɛ-shrinkage) -251         
            
  Final Model Bootstrap   
        95% CI 
Parameter Estimation  RSE% Median LL UL 
AS coefficient 2.08 7.44 2.09 1.8 2.39 
AS exponent 0.628 2.94 0.628 0.59 0.66 
PSA on AS coefficient -0.481 -25.2 -0.473 -0.77 -0.24 
            
Inter-drug variability (IDV)           
AS coefficient 0.983 30.5 0.973 0.48 1.65 
η AS exponent 0.413 29.2 0.406 0.10 0.30 
            
Residual error model           
σadd 0.180 --- 0.180 --- --- 
Eta Shrinkage (ŋ - shrinkage)           
AS coefficient 3.45         
AS exponent 2.77         
Epsilon shrinkage (Ɛ-shrinkage) -251         
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Table 3. Physicochemical and DMPK properties of compounds in the database 
 N Mean Median Range Q1 Q3 
Molecular Weight (MW) (Da) 251 407 360 101 -1878 277 466 
Polar Surface Area (PSA) (Å) 251 111 90 3 - 662 60 146 
Rotatable Carbon Bound (RCB) 251 6.42 5 0 - 59 3 8 
Calculated Logarithm of the Octanol-Water Distribution 
Coefficient (ClogD) 249 -0.345 -0.1 
-11.6 - 
14.4 -2.3 1.7 
Estimated Logarithm of the Octanol-Water Partition 
Coefficient (ElogP) 251 1.465 1.4 1.6 - 4.9 0.59 2.1 
Percent of Ionization (%Ioni) 243 69.8 99.1 0 - 100 10.5 100 
Plasma Protein Binding (PPB) 251 73.8 83 15 - 99.8 57 94 
Central Nervous System Absorption (CNSa) 251 0.593 0.7 0 - 1 0.18 0.95 
Apparent Permeability through Cell Membrane (Papp) 251 16.5 14 1.5 - 46 3.75 27 
Human P-glycoprotein Transporting Property (PGPh) 251 2.47 1.4 0.48 - 13 0.8 3.35 
       
Oral Absorption Property (OrlA) 249      
good 130 
     
moderate 35      
bad 84      
Elimination Pathway (Elim) 251      
excretion 67 
     
metabolism 161      
both 24      
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Figure 1. Distribution of the physicochemical and DMPK properties 
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Figure 2. Goodness of fit plots of the final AS nonlinear MEM model. (A) and (D). Population Model Predicted versus Observed CLs; 
(B) and (E). Individual predicted based on final model versus observed CLs; (C). Conditional weighted residuals versus log 
transformed body weight; 
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Figure 3. Distribution and central tendency of Observed versus Model Predicted Human CL  
1) Observed human CLs distribution 
a.  
 
 
 
 
b.  
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2)  Final model predicted human CLs distribution 
c. 
 
 
 
d. 
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Figure 4. Distribution of Model Estimated AS Exponent versus Literature Reports 
(A). Final model estimated AS exponent distribution (n = 251) 
 
(B). Literature reported AS exponent distribution (n = 115)(38)  
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Appendix 1. Correlation between ETA1 and ETA2 with Potential Covariates 
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Appendix 2. Individual Drug Observed versus Model Predicted CLs Cross Species from the Final AS Model 
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Appendix 3. Final Model Control File 
$PROB Allometric scaling exploration run56 ; run56.mod 
 
$INPUT ID sub DV TIME MDV CNSa lgDH Papp Ppb PGPh OrlA Mw Psa RotB ClogD Ioni 
ELIM1 ELIM2 ELIM3  
 
$DATA AS.4.csv IGNORE = C 
 
$PRED ; Calculate the prediction of the model 
 ;  COEF vs. Psa 
    COEFPsa = (Psa/89)**THETA(3) 
 
    TVCOEF=THETA(1)*COEFPsa 
 
    TVSLOP=THETA(2) 
    COEF = TVCOEF * EXP(ETA(1)) 
    SLOP = TVSLOP * EXP(ETA(2)) 
  
    F = COEF+SLOP*TIME 
    IPRED = F 
    IRES = EXP(DV) - EXP(F) 
    IWRES = IRES/EXP(F) 
    Y = F + ERR(1) 
 
$THETA ; Starting estimates for the structural model 
     (0, 1.3) ; COEF 
     (0, 0.596) ; SLOP 
     -0.3       ; COEFPsa 
 
$OMEGA ;  
     0.3302 
     0.005 
 
$SIGMA; 
    0.03162 FIX 
 
$ESTIMATION SIG=3 MAX=2000 PRINT=1 METHOD = 1; 3 significant digits, 2000 
iterations max 
 
$COV 
 
$TABLE ID sub TIME DV MDV COEF SLOP ETA(1) ETA(2)CNSa lgDH Papp Ppb PGPh 
Mw Psa RotB ClogD Ioni OrlA ELIM1 ELIM2 ELIM3 NOPRINT ONEHEADER 
FILE=patab56 
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$TABLE ID sub TIME DV MDV COEF SLOP CNSa lgDH Papp Ppb PGPh Mw Psa RotB 
ClogD Ioni  ONEHEADER FILE=cotab56 NOPRINT 
 
$TABLE ID sub TIME DV MDV COEF SLOP OrlA ELIM1 ELIM2 ELIM3 ONEHEADER 
FILE=catab56 NOPRINT  
 
$TABLE ID sub TIME DV MDV COEF SLOP IPRED IWRES CWRES IRES  ONEHEADER 
FILE=sdtab56 NOPRINT 
 
$TABLE ID sub TIME DV MDV COEF SLOP ETA(1) ETA(2) IPRED IWRES CWRES IRES 
CNSa lgDH Papp Ppb PGPh Mw Psa RotB ClogD Ioni OrlA ELIM1 ELIM2 ELIM3 
ONEHEADER FILE=alltab56 NOPRINT  
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CHAPTER 3 
 
MODELING AND SIMULATION APPROACH FOR CHARACTERIZING 
AND EVALUATING THE SINGLE SPECIES ALLOMETIC SCALING 
 
1_Abstract 
Objective: Animal and human systemic clearance (CL) data were collected and used for the 
characterization and evaluation of single species allometric scaling (AS). Potential effects of 
drug physicochemical and pharmacokinetic (DMPK) properties on the estimated single species 
AS exponents were also investigated. 
Methods: Single species AS was characterized using extensive literature collected data to 
estimate the single species AS exponent distribution and central tendency. Comparisons of single 
species AS exponent estimates based on different species and commonly reported values were 
conducted. Correlations were investigated between the estimated AS exponents and the 
physicochemical and pharmacokinetics (DMPK) properties of the compounds examined. For a 
hypothetical compound under drug development, stochastic simulations, based on the uncertainty 
obtained from the data and modeling results from this work, were performed in order to capture 
the uncertainty in the predictions of human CL from single species methods. 
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Results: The estimated single species AS exponents were consistent with literature reports and 
the commonly used exponent values. There were no obvious correlations identified between the 
estimated AS exponents and the physicochemical properties or pharmacokinetics (DMPK) 
properties of the compounds. This analysis utilizing a large data set increased the confidence in 
applying the exponents of single species methods. Further, it offers robust estimates on the 
uncertainties, which should be incorporated in the practice of single species allometry.  
 
2_Introduction 
     During drug development, interspecies scaling is a commonly used tool to predict 
pharmacokinetic parameters in humans from animal data and for the first in man dose selection 
(1). Allometric scaling has become one of the most widely used approaches for human CL 
prediction based on measured animal species CL(2). Allometric scaling was developed based on 
the principle that the relationship between organ size, regional perfusion and body weight of 
mammals could be characterized by a simple power law expression, Y = a Wb, where W is 
species body weight, Y in this case is CL, and a and b are the allometric coefficient and exponent, 
respectively.  
      Because of the empirical nature of AS and the various reported prediction failures for human 
CL through AS, there have been a number of attempts to refine the simple AS to improve its 
predictability on human CL. The modification and correction methods to simple AS include 
using brain weight (BW) and maximum life span (MLP) corrections (2)(3) utilizing the “rule of 
exponents (ROE)”, an empirical correction technique which lowers the prediction of human CL 
when a relatively high AS exponent is obtained through simple AS (4), in vitro metabolic CL 
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correction (5), correction for the unbound fraction of drug in plasma (6) and correction for 
plasma protein binding differences between animals and humans (7). The results of these 
correction factors on simple AS, however, have been controversial (5). The ROE method has 
gained substantial support and did improve human CL prediction in some cases. However, some 
researchers analyzing larger AS data sets reported that the ROE method provided no significant 
improvement for human CL predictions compared to simple AS (8)(9).  
     Along with the debates on the simple AS and its correction approaches, another major 
controversy in AS is whether to use varying-exponent allometry or fixed-exponent allometry (8-
12). Interspecies scaling extrapolation based on the empirical power function whose exponent 
(and coefficient) estimated from animal data is termed varying exponent AS. This includes 
simple AS as well as AS with any modifications and correction factors. The limitations and 
intrinsic defects of this approach have been extensively discussed (3)(4)(5)(9)(13)(14). Tang and 
Mayersohn  demonstrated that the functionality of applying correction factors in simple AS is  
essentially equivalent to multiplication of some predetermined constant values to the predicted 
human CL obtained from simple AS and has no bearing on PK parameter measurements in the 
animal species (15). Tang et al. further showed, from both mathematical/statistical theory and 
experimental data, that the varying-exponent AS approach or the utilization of various correction 
factors should not be employed in interspecies scaling of pharmacokinetic parameters (16). 
Currently, fixed-exponent AS is commonly used in the pharmaceutical industry. For scaling CL 
between adults and children, AS with a fixed exponent of 0.75 is often applied (17). Based on a 
data-driven approach, Tang and Mayersohn derived one and two species-based AS methods for 
human CL prediction using animal CL data. In their results, the single species AS methods 
demonstrated as CLhuman/kg = 0.152 ×  CLrat/kg, CLhuman/kg = 0.410 ×  CLdog/kg and CLhuman/kg 
93 
 
= 0.407 ×  CLmonkey/kg, which mathematically were equivalent to exponents of 0.648, 0.494 and 
0.659 for rat, dog and monkey single species AS methods with the assumption that the median 
body weights of human, rat, dog and monkey at 70 kg, 0.33 kg, 12 kg and 5 kg, respectively (10).  
     Generally AS methods have been developed based on relatively small sets of data (12). One 
common criticism of allometry is on its empiricism, which is heavily dependent on the data 
selection and sample size. Inconsistency and controversies among different allometric methods 
or models were partially due to the limited data sets that have been analyzed. One of the major 
purposes of this investigation was to evaluate the current single species methods and to propose 
new models based on the analysis of a larger data set.  In this study, single species AS was 
performed using a large diverse literature (n = 251) data set (in rat, dog, monkey and human) of 
CL values, and the AS exponents were estimated for single species AS predictions of human CL  
based on rat, dog or monkey DMPK data. The derived single species AS exponent distribution 
and central tendency was compared with commonly used single species AS exponents. In order 
to obtain possible explanations for the large inter-compound AS exponent variability, potential 
correlations between the estimated single species AS exponents versus the corresponding 
physicochemical and DMPK properties of drugs were investigated. For a hypothetical compound 
under drug development, simulations were performed for human CL prediction by incorporating 
the central tendency and uncertainties derived from this analysis. 
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3_Methods 
Data collection 
     Two hundred and fifty one sets of intravenous administered drug systemic CL data were 
collected from the literature. The two-dimensional physicochemical and topological descriptors 
of the collected compounds were computed with an in-house program (Chemoinformatics, 
Monika Five v 1.2), which predicts physicochemical and pharmacokinetic properties based on 
chemical structures. After initial screening and correlation exploration, a total of 12 
physicochemical and drug metabolism and pharmacokinetics properties of drugs were selected 
for the correlation investigation with the estimated single species AS exponents. The 
physicochemical and pharmacokinetic properties of drugs were: 1) molecular weight (MW);  2) 
polar surface area (PSA); 3) rotatable carbon bond (RCB); 4) calculated logarithm of the octanol-
water partition coefficient (cLogP); 5) calculated logarithm of the octanol-water distribution 
coefficient (clogD;  6) ionization status (%IONI);  7) oral absorption property (good, moderate, 
bad) (OrlA); 8)  plasma protein binding (PPB); 9) central nervous system absorption (CNSa); 10) 
apparent permeability through cell membranes (Papp); 11) human P-glycoprotein transporting 
property (PGPh); 12) elimination pathway (by metabolism; by renal elimination; by both) 
(ELIM). These parameters are defined and discussed in Chapter 2.  Out of the 251 drugs data set, 
three separate data sets were extracted: CL in rat (CLrat) versus CL in human (CLhuman), CL in 
dog (CLdog) versus CL in human (CLhuman), and CL in monkey (CLmonkey) versus CL in human 
(CLhuman). In each of the extracted data sets, the corresponding physicochemical and DMPK 
properties for each drug were carried along into the newly compiled data sets.  
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Single species AS 
     For each single species AS data set, CLs of each compound were plotted against its 
corresponding animal/human body weights on a log-log scale according the following AS 
equation: 
log𝐶𝐿 = log 𝑎 + 𝑙𝑜𝑔𝑊                              (1) 
where W is body weight, and a and b are the coefficient and exponent, respectively. In this study, 
the CL in different species were assumed commonly used body weight of 0.33 kg, 12 kg, 5 kg 
and 70 kg for rat, dog monkey and human, respectively. Derived from the simple AS equation, 
the following equation was utilized to calculate the single species AS exponent (slope) for each 
drug, taking rat versus human single species AS as an example: 
𝑏 = log(𝐶𝐿ℎ )−log  (𝐶𝐿𝑟)
log(𝑊ℎ )−log  (𝑊𝑟)                               (2) 
where, b is the single species AS exponent (slope),  CLhuman and  CLrat are the observed human 
and rat CL, and Whuman and Wrat represent body weight in human and rat, respectively.  
     Three single species allometric methods were obtained, namely rat, dog and monkey single 
species fixed allometry. The central tendency and distribution of the estimated exponent from 
each method were estimated and compared with the literature reported and commonly used one 
AS species exponent values. Descriptive statistical analysis of three sets of AS exponent 
estimations was conducted for mean, median and ranges by using software R 2.8.1.  
Correlation between AS Exponent and Physicochemical and DMPK properties 
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     The exponents from each method were first plotted against each estimated physicochemical 
and DMPK properties (potential covariate) to identify possible correlations. As a further 
evaluation, potential correlation between exponent (b) and each continuous potential covariate 
was tested by significant test in a linear regression model at the 0.001 significance level.  For a 
categorical covariate, the estimated exponents for different drugs were grouped by the 
categorical covariate. One way analysis of variance (ANOVA) was thereafter employed to test 
the difference between grouped exponents. A p-value < 0.001 was considered statistically 
significant.  
Simulations for Human CL Prediction  
     In order to demonstrate the practical utility of the single species AS approaches developed in 
this study, a hypothetical drug was proposed for each single species AS method. Hypothetical 
drugs with assumed mean CLs of 7.59, 103, and 39.8 mL/min for rats, dogs and monkeys, 
respectively, were used for further simulation. Those assumed CLrat , CLdog and CLmonkey were the 
corresponding median CLs of rat, dog and monkey estimated form the original data set. For each 
single species AS approach, Monte-Carlo simulation (n = 10,000) of exponents was performed 
based on the estimated exponent distribution, which was assumed to be normal distributed, N 
(mean, SD), where mean and SD were the average exponent and standard deviation. Taking rat 
single species AS as an example and based on the following derived equation (3) from the simple 
AS: 
𝐶𝐿ℎ𝑢𝑚𝑎𝑛 = 𝐶𝐿𝑟𝑎𝑡 × (𝑊ℎ𝑢𝑚𝑎𝑛𝑊𝑟𝑎𝑡 )𝑏                       (3) 
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where, b is the single species AS exponent (slope) . For each single species method, 10,000 
human CLs were thereafter predicted. The simulations were performed in R (R version 2.11.1). 
The distribution of the predicted human CLs based on different single species AS methods were 
illustrated in histogram plots. At the same time, as a further distribution exploration, the 
predicted CLs were also log transformed and plotted in linear scale using R program. 
4_Results and Discussion 
     Within the main data set (n = 251), there were 249 drugs having both rat and human data; 231 
having both dog and human CL values; 156 having both monkey and human CL values. These 
three extracted data sets, CLrat versus CLhuman, CLdog versus CLhuman and CLmonkey versus CLhuman 
data sets, were utilized for the estimation of the single species AS exponent for each drug in each 
approach. The distributions and central tendencies of AS exponents for each single species AS 
method were demonstrated in Figure 1. The statistics of the exponent distributions are shown in 
Table 1. The mean rat single species AS exponent in this study was estimated to be 0.667, which 
was consistent with the previously reported rat single species AS exponent (0.66) based on 54 
extensively metabolized drugs (12). Tang and Mayersohn, using a data driven (n = 102) 
statistical optimization approach (by minimizing the objective function of average absolute fold-
error and optimizing the objective function of average fold-error at 1), derived single species 
methods for predicting human drug CL using animal CL from rat, dog and monkey. In their 
results the single species AS exponents were mathematically equal to 0.647, 0.494 and 0.659 for 
rat, dog and monkey single species AS approaches, respectively. Their results were very close to 
the mean exponents established in the present study with rat, dog and monkey single species AS 
exponents estimated at 0.667, 0.519 and 0.659, respectively.  Although Tang and Mayersohn’s 
data (N = 102) and the data in this work shared some common drugs, the data size in this work 
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was larger, thus, the results from the current study have provided solid evidence and greatly 
strengthen the usage of the widely accepted single species AS exponents. Interestingly, the 
exponents for the rat and monkey method showed relatively smaller inter-compound variability 
than that for the dog method.   
     Correlation between the three sets of AS exponents versus potential covariates (the estimated 
physicochemical and DMPK properties of the selected compounds) were inspected by visual 
exploration as well as statistical tests. The results are presented in Table 2 and Appendix 1. For 
the visual inspections, there were no obvious correlations identified for any pair of a potential 
covariate with a single species AS exponent. Through the statistical tests, there was no 
statistically significant correlation (for continuous potential covariates) or any significant 
difference among groups (categorical covariates) (P-value < 0.001). Considering the size and 
diversity of the collected literature data, it is not very likely that these physicochemical 
properties play a role in AS. Mechanistically, with the exception of renal filtration, clearance is 
mainly governed by biochemical processes such as enzymatic biotransformation and transporter 
mediated transportation. Renal reabsorption is largely dependent on plasma drug-protein binding 
and permeability.  The current physiochemical properties analyzed may be more relevant to the 
distribution rather than the elimination of chemicals.  This is consistent with the well-recognized 
facts that volume of distribution may be well predicted purely based on physiochemical 
properties (18) while for CL, there have been few successful reports with in silico approaches 
(19). 
     To further explore the practical application of the current developed single species AS models, 
Monte Carlo simulations were performed for each single species AS approach to predict human 
CL for a hypothetical drug, in order to capture the uncertainties of the human CL predictions. 
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Based on the exponent and their distributions estimated in this study for rat, dog and monkey 
single species AS method: N (0.667, 0.25), N (0.519, 0.80) and N (0.659, 0.36), respectively, 
10,000 exponents were simulated for each approach. Thus, for a hypothetical drug with a mean 
drug CL of 7.59 ml/min, 103.2 ml/min and 39.8 ml/min for rat CL, dog CL and monkey CL, 
respectively, 10,000 corresponding human CLs were thereafter estimated for each single species 
AS approach. The predicted human CL distributions were demonstrated in the in Figures 2, 3 
and 4.  For all three methods, the predicted human CLs were log transformed and plotted in 
linear scale. As expected, the predicted human CLs followed a log normal distribution. All three 
methods are associated with relatively large uncertainty in predicted clearance values. The 
median predicted human CL based on rat, dog and monkey methods, was 268.2 ml/min with 90% 
quantiles at 29.2 – 2385.2 ml/min, 258.3 ml/min with 90% quantiles at 26.5 – 2649.8 ml/hr, and 
226.2 ml/min with 90% at 44.9 – 1083.1 ml/hr, respectively.  For the rat, dog and monkey single 
species AS approaches, the ratios of 95% to 5% human CL prediction are 81.8, 110.1 and 24.1, 
respectively. Monkey single species AS approach showed the narrowest human CL prediction 
ranges and appeared to have better predictability compared to rat and dog single species AS.  
     Typical allometry analyses reported one-number prediction without acknowledgement of 
prediction uncertainty. This type of individual and retrospective analysis misses an important 
part of the prediction sciences, which is the uncertainty. In reality, the uncertainty exists for all 
CL predictions given the empirical nature of allometry scaling, therefore, uncertainty in 
prediction should be incorporated into the predictions. The current investigation provides a 
framework and quantitation of these uncertainties for the single species AS, thus representing a 
realistic risk assessment and creating a scientifically sound decision-making avenue in human 
PK and dose prediction. It is noteworthy that the uncertainty for the monkey method appeared to 
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be the smallest. This probably makes sense in term of species proximity of monkey to humans; 
thus, the biochemical processes may be most similar to those in humans. Other research also 
suggested this (9)(10).  
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Figure 1.  Single species AS exponent central tendency and distributions based on literature 
collected data of CLrat-CLhuman (n = 249), CLdog-CLhuman (n = 231) and CLmonkey-CLhuman (n = 156)
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Figure 2. Distributions of predicted human CL (ml/min) values for 10,000 simulations based on 
rat single species AS approach. Linear scale and log-transformed scale are presented in upper 
and lower plots, respectively.  
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Figure 3. Distributions of predicted human CL (ml/min) for 10,000 simulations based on dog 
single species AS approach. Linear scale and log-transformed scale are presented in upper and 
lower plots, respectively.  
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Figure 4. Distributions of predicted human CL (ml/min) for 10,000 simulations based on 
monkey single species AS approach. Linear scale and log-transformed scale are presented in 
upper and lower plots, respectively.  
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Table 1. Summary statistics of the estimated AS exponent distribution for single species AS rat, 
dog and monkey methods based on the literature data  
 N Mean  Median Standard Deviation Range 
Rat AS Exponents 249 0.667 0.666 0.25 -0.83 – 1.53 
Dog AS Exponents 231 0.519 0.570 0.80 -3.49 – 4.92 
Monkey AS Exponents 156 0.659 0.701 0.36 -0.48 – 2.07 
 
Table 2. Statistical analysis of the correlations of exponents from three different single species 
AS with the physicochemical and DMPK properties 
  P - value 
 Physicochemical and 
DMPK properties 
Rat versus 
Human 
Dog versus 
Human 
Monkey versus 
Human 
Significant Test in 
Linear Regression 
  
MW 0.839 0.303 0.700 
PSA 0.267 0.919 0.145 
RCB 0.863 0.915 0.064 
cLogP 0.076 0.008 0.032 
cLogD 0.852 0.083 0.039 
%ionized 0.124 0.768 0.902 
PPB 0.006 0.001 0.013 
CNSa 0.723 0.562 0.028 
Papp 0.118 0.280 0.048 
PGPh 0.977 0.297 0.022 
 One Way 
Analysis of 
Variance  
OrlA 0.195 0.685 0.001 
ELIM 0.804 0.664 0.060 
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Appendix 1. The correlations between the single species AS exponents (from the CLrat versus CLhuman, CLdog versus CLhuman, CLmonkey 
versus CLhuman data sets) with the estimated physicochemical and DMPK properties 
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CHAPTER 4 
 
EVALUATION OF METHODS IN ANALYZING ALLOMETRIC POWER 
FUNCTIONS IN PREDICTING HUMAN PHARMACOKINETICS: A 
COMPARISON OF LOG-LOG TRANSFORMATION FOLLOWED BY 
LINEAR REGRESSION VERSUS DIRECT NONLINEAR REGRESSION 
 
1_Abstract 
Objective: Animal and human systemic clearance (CL) data were collected and used for 
evaluation and cross comparison of methodologies in allometric functions analysis, namely the 
log-log transformation followed by linear regression (LL-LR) and direct nonlinear regression 
(NLS) with different weighting schemes. Central tendency and distribution of the allometric 
exponents were evaluated and compared. More importantly, the human CL prediction 
performance was evaluated among the methods.  
Methods: Pharmacokinetic data following intravenous administration for 251 drugs with CL in 
at least 3 species (including human) were used in this study. LL-LR and NLS functions with 
weighting functions of 1/CL1/2, 1/CL, 1/CL3/2, 1/CL2, 1/CL3 and 1/CL4 were coded in R Software 
for analysis. Allometric exponents, statistics (including root mean square error (RMSE%), BIAS% 
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and R2), and the prediction performance (individual predicted/observed, absolute average fold-
error (AAFE), average fold-error (AFE), ranges, etc.) were evaluated across different methods.   
Results: The LL-LR method and the NLS with 1/CL2 weighting resulted in the most similar 
allometric exponent with central tendency around 0.668.  This value is close to what has been 
reported in literature. In addition, these two methods provided the best predictability among the 
different methods, which supports the widely used LL-LR method used for pharmacokinetic 
interspecies scaling. Furthermore, the statistic indices, R2, RMSE% and BIAS%, were all shown 
to bear poor correlations with the prediction performance. Lastly, LL-LR analysis corrected by 
MLP and BrW were demonstrated to be no better, or even worse, than the direct LL-LR method.  
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2_Introduction 
     Allometric scaling (AS) is grounded on the similarity of anatomical, physiological and 
biochemical variables in mammals (1)(2). The application of allometry was introduced into the 
biology field by Sir Julian Huxley in his 1932 book entitled  Problems of Relative Growth, which 
defined the concept of “size and its consequence”(3). Basal metabolic rate (BMR) with body size 
is one of the most investigated AS relationships in comparative biology. AS being introduced 
from comparative biology by Dedrick in 1970s has been widely used in pharmacokinetics (PK) 
for the prediction of human PK parameters, including drug clearance (CL) based on in vivo 
animal data (2)(4). The AS relationship can be expressed mathematically by the power function 
PK = a (W)b, where PK, in this case, is CL, W is species body weight, a is the allometric 
coefficient and b is the allometric exponent. 
     In the traditional comparative biology and pharmacokinetic method of analysis, the log 
transformation of both sides of the AS power function [Log(PK) = Log(a) + b Log(W)] is 
followed by linear regression (LL-LR)  to obtain the allometric exponent and coefficient (5)(6). 
However, there has been little evidence to demonstrate that the LL-LR method is the most 
optimal for solving the power law function to predict human PK. As one of the principal 
techniques used in predicting human PK from animal data, AS has played an important role in 
drug discovery.  Failure in predicting human PK would substantially impact drug development 
(7). 
LL-LR: History of Applications in Comparative Biology and Pharmacokinetics 
     One of the major reasons that LL-LR has been historically popular is its easy usage.  This was 
particularly true and important in the era when computers were not available. The LL-LR 
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method could virtually be done manually. The first step is to linearize the nonlinear data by log-
transformation of X and Y data. The second step, linear regression, could be done graphically. 
The analytical solutions of the coefficient and exponent can also be derived from the 
minimization of least-squares. This method was widely used in comparative biology, of which 
the allometric analysis of the basal metabolic rate (BMR) versus body weight was the most 
famous and extensively investigated (8). By LL-LR analysis, the well-accepted ¾ power law was 
developed, which states that the animal’s metabolic rate scales to the ¾ power of the animal 
weight (8, 3, 9). In 1949, Adolph et al. analyzed the physiological parameters, such as blood flow, 
liver weight, and others, versus body weight across animal species, using the LL-LR method and 
concluded that those physiological parameters followed the allometric model as well (10). 
Dedrick first introduced the allometric scaling of PK parameters for drugs (2). Shortly after, 
Boxenbaum extensively expanded the concepts of allometric scaling introducing 
pharmacokinetic time, maximum life span potential (MLP) and brain weight (BrW) correction 
(11, 12, 14). Following the seminal works of Dedrick and Boxenbaum, reports of allometric 
scaling of PK parameters, have escalated. Later, a variety of derivatives of allometric methods 
were proposed and used, such as “rule of exponents”(13), correction of in vitro clearance and(14) 
correction of protein binding (15). Nevertheless, all these methods use the LL-LR analysis 
method.  
LL-LR: Statistical Fundamentals 
     LL-LR analysis of the AS power function basically assumes the model with a multiplicative 
error as in Eq. (1),  
𝐶𝐿 = 𝑎 × 𝑊𝑏× exp(ɛ)              (1) 
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where CL is the drug clearance and W is the body weight of the corresponding species, a is the 
allometric coefficient, and b is the allometric exponent and ɛ is the inter-drug variability. By 
taking the log of both sides of the equation, a linear model with additive error is derived, based 
on which a linear regression of log(CL) versus log(W) could be performed as shown in Eq.(2):  
log(𝐶𝐿) = log(𝑎) + 𝑏 × log (W) +  ɛ            (2) 
Therefore, LL-LR is built upon the following principal assumptions: linearity of the relationship 
between the dependent variable, Log(CL), and the independent variable Log(W); independence 
of the errors meaning there is no serial correlation;  homoscedasticity of the errors, which 
presents constant variance of the errors; and normality of the error distribution. Violation of any 
of these assumptions will cause a regression model to be biased or misleading (16). 
     Data transformation is often applied in statistical analysis. Validation of the assumptions on 
the original data distribution has become a normal practice before data transformation is 
employed in statistical analysis. In allometric analysis, however, this has been often neglected or 
not feasible, due, in part, to scarcity of the data. Typically PK parameters from only three or four 
species are employed. The regular assumption testing, such as constant variance and normality 
test of residuals, was often not feasible. Another limitaton of LL-LR is that log transformation 
compresses the data distribution in an unbalanced way. The high end of the distribution is 
affected more than the low end. The straight line fitted to the transformed data will exaggerate 
the influence of small values of the response variable. The small changes in slope  may translate 
into large changes in estimates in the original scale (17-19). 
     In PK, Tang and Mayersohn derived a mathematical equation of LL-LR, which clearly shows 
that the contribution of PK parameters to the human prediction is different among animal species, 
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and the differences are largely determined by the animal body weight rather than the measured 
PK parameters in different species. This presents another defect  in using  LL-LR in analyzing 
the allometric power function (20). 
      In comparative biology, there have been a few limited reports, which challenged the use of 
LL-LR in analyzing allometric relationships, mainly focusing on the basal metabolic rate versus 
body weight. For example, the ¾ law has been challenged in a statistical perspective that the ¾ 
exponent could not be statistically differentiated from an exponent of 2/3 (8, 21, 22, 9). Others 
also reported that the exponent of basal metabolic rate could be different from that based on LL-
LR if different methods are used for analysis of power function (23).  
     Another important note to the LL-LR method is that the coefficient of determination (R2) is 
an insufficient or inappropriate statistical index in assessing the correlations of nonlinear models 
(24, 25). Often high R2 in allometric analysis has been used to claim excellent correlation and 
high confidence in prediction. It has been shown, however, that the R2 is theoretically expected 
to be high for LL-LR with typical allometric PK data as W and CL typically covers more than a 
100-fold range.   Further, there is weak correlation between prediction performance and R2 (25). 
     In summary, the allometric relationship is largely empirical and the LL-LR method is 
associated with assumptions that cannot be statistically validated. However, the ready 
availability of computers allows for direct nonlinear regression. In this study the performance of 
the direct nonlinear regression methods encompassing different weighting functions was 
compared to the LL-LR method in analyzing the AS power function, including their accuracy 
and precision on human CL prediction. The simple direct LL-LR method was also compared 
with the MLP and BrW corrected LL-LR methods. 
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3_ Methods 
Data Set 
     Pharmacokinetic data following intravenous administration for 251 drugs with CL in at least 3 
species, including humans, found in the literature were used as the main data set in this study. 
This main data set (n = 251) was then used as the data set for the first analysis in this study to 
retrospectively evaluate AS exponents. Out of the main data set, the compounds with CL data 
from 3 animal species, excluding humans, were extracted and used as the data set (n = 133) for 
the second analysis in this study to conduct human CL prediction comparison across methods. 
This data set was also used for the third analysis in this study to evaluate three statistical indices 
for prediction performance. 
Data Analysis Strategy 
     Two major methods were used to estimate the AS parameters. The first method of analysis 
employs linear regression analysis of log transformed data.  The second method used a weighted 
nonlinear regression by minimizing the objective function through an iteration process judged by 
the Gauss-Newton optimization algorithm.  
     The methodology in this study included three different analyses. The first analysis compared 
NLS and LL-LR on each drug in the main data set, which includes human CLs, to retrospectively 
estimate the distribution and central tendency of the AS exponent by different methods and 
weightings. In the second analysis, NLS and LL-LR were performed on each compound in the 
data set which did not include human CL values, to obtain the AS exponents. Based on these 
results, the predicted human CL for each compound was calculated and compared with the 
observed human CLs. The goal of the second analysis was to determine the accuracy and 
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precision of human CL prediction across different approaches. The third analysis was to evaluate 
correlation of the commonly used statistical indices R2, RMSE and bias versus human CL 
prediction performance. Poor description of coefficient of determination using R2 for a nonlinear 
model has been well recognized (26)  The relative root mean squared error (RMSE), which is 
used to describe precision and the mean prediction error (bias), was considered to provide better 
description of predictive performance (26). The RMSE% and bias% for direct nonlinear 
regression method with different weightings and LL-LR were calculated. These RMSE and bias 
values were evaluated against the human CL prediction performance, with the attempt to assess 
the appropriateness of using RMSE and bias as the statistical index, rather than R2. 
LL-LR  
     The AS approach of LL-LR was performed for each compound in the data sets  with human 
CLs and the data set without human CL values). After taking the logarithm of both sides of the 
nonlinear AS power equation: log(CL) = log(a) + b × log(W), a linear regression function was 
applied to obtain parameter estimates log(a) and b using software R. This operation was based on 
the assumption that log-transformed inter-drug variability is additive and follows a normal 
distribution.  
     As for the comparison investigation on MLP and BrW corrected LL-LR, from the MLP and 
BrW corrected AS method original paper, the MLP of 5.24, 18.4 and 22.9 years, and BrW of 
2.48, 63.7 and 66.0 grams, for rat, dog and monkey, respectively, were introduced to the log 
transformed CL values. Linear regression was thereafter conducted on the MLP or BrW 
corrected CLs to get human CL prediction (CL/MLP or CL/BrW). A median human MLP of 
93.5 years and BrW of 1533 grams were then used to calculate the predicted human CLs (11). 
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Nonlinear Regression  
     The NLS with different weightings were directly performed by fitting the allometric equation 
to each compound in  both data sets. The Gauss-Newton algorithm was applied for optimizing 
the objective function values. The weights were set as the reciprocal of CL raised to various 
powers: 1/CL1/2, 1/CL, 1/CL3/2, 1/CL2, 1/CL3, 1/CL4.  Initial values of the coefficient and 
exponents were set at 10 and 0.6, respectively. For each weighting, there were a few compounds 
for which NLS could not succeed in minimization with the standard set of initial values. A 
manual adjustment of initial values of either coefficient and/or exponent was introduced. This 
adjustment was conducted repeatedly until successful minimization was achieved.  
Assessment of Prediction Performance 
     Absolute average fold-error (AAFE) was used to assess the precision of predictions (27) 
defined as, where n is the total number of compounds analyzed as in Eq. (3): 
𝐴𝐴𝐹𝐸 = 10∑�log (𝑝𝑟𝑒𝑑𝑜𝑏𝑠 )�/𝑛           (3) 
     A smaller AAFE indicates a better prediction performance. For example, AAFE at 2 means 
an overall “averaged” prediction is 2-fold over or under the observed values. 
     Average fold-error (AFE) was used to assess the overall bias of prediction, defined as Eq. (4): 
𝐴𝐹𝐸 = 10∑log (𝑝𝑟𝑒𝑑𝑜𝑏𝑠 )/𝑛          (4) 
     An AFE value <=1, =1, and >1 means there is an overall under, no, and over-predictions 
relative to the observed values, respectively. In addition, the prediction performance was also 
assessed by the percentage of fold-error (Predicted human CL/Observed human CL) out of a 
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certain range, such as [-0.1, 10] and [0.3, 3]. These ranges represent the commonly used 
prediction percentage 10 and 3 folds, respectively. 
     The human CL prediction performance was also evaluated by the bias and root mean square 
error. Bias and the root mean square error (RMSE) were expressed as Eq. (5):                                             
𝑏𝑖𝑎𝑠  % = � �𝑌𝑖 − 𝑌𝚤��/𝑛𝑛𝑖
� 𝑌𝚤�/𝑛𝑛𝑖  
 
𝑅𝑀𝑆𝐸 % = �� (𝑌𝑖−𝑌𝚤�)2/(𝑛−2)𝑛𝑖
� 𝑌𝚤�/𝑛𝑛𝑖            (5)         
 
where n is the number of animal species for each compound.  
R Software and Programming 
     The software R 2.8.1 was used for all analyses. The NLS function is used for estimating 
parameters via least squares. It assumes that the errors (𝜀) are independent with variance 𝜎2/w, 
where w is the known weighting and 𝜎2 is the unknown variance to be estimated. Different 
weighting schemes as described above were used with NLS.  Unlike linear regression, where the 
parameter estimates can be solved analytically, nonlinear regression by minimization of least-
squares doesn’t offer an analytical solution. Rather, NLS uses an iterative procedure, which 
searches for the minimizer of the least-square via an algorithm. A Gauss-Newton algorithm is the 
default with NLS. The programming codes for NLS are provided in Appendix 1. And, the 
example R code for the programming of RMSE%, BIAS% and R2 are presented in Appendix 2. 
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4_Results and Discussion 
 
     For the first analysis based on the data set that includes human CLs, the estimated AS 
exponent distributions and central tendencies estimated from NLS with different weightings and 
LL-LR are presented in Figure 1 and Table 1. The estimated AS exponent distributions through 
NLS with different weightings versus LL-LR are generally consistent. Among them, the AS 
exponent distribution estimated from NLS with weighting of 1/CL2, 1/CL1, 1/CL1.5 demonstrate 
similar distributions compared to LL-LR. As for the comparison of AS exponent central 
tendencies, the estimated AS exponent median value of 0.674 through NLS with weighting 1/CL 
is most similar to that of LL-LR (0.668). At the same time, the other NLS with weightings 1/CL2 
and 1/CL1.5 also provided AS exponent estimations of 0.651 and 0.692, respectively, within the 
±5% difference from LL-LR. For the weighting 1/CL0.5, 1/CL3 and 1/CL4, there were relatively 
bigger differences compared to results from LL-LR estimation. These results demonstrated that 
through the approaches of LL-LR and NLS with weighting schemes of 1/CL2, 1/CL1, 1/CL1.5 to 
perform AS could lead to similar AS exponent estimations and further similar human CL 
predictions. Given there are substantial outliers at the high end for NLS with weighting schemes 
of 1/CL1, 1/CL1.5, the NLS approach with weighting 1/CL2 was considered to be the most similar 
method to LL-LR. 
     It is worthwhile to mention that the AS exponent estimation results, both distribution and 
central tendency through NLS with weighting 1/CL2, 1/CL1, 1/CL1.5 as well as LL-LR are similar 
to what Hu et al. reported in 2001 (29). In conclusion, the results from our study based on this 
large diverse data set suggests the AS exponent values for CL around the exponent rule of 2/3 
(0.668).  
129 
 
Table 1. Estimated AS exponent central tendencies and percent difference between NLS with 
weightings compared to LL-LR based on data set including humans 
 
Weighting function AS Exponent % Difference Compared to LL-LR 
1/w0.5 0.620 -7.2 
1/w1 0.674 0.90 
1/w1.5 0.692 3.6 
1/w2 0.651 -2.6 
1/w3 0.581 -13 
1/w4 0.574 -14 
LL-LR 0.668 --- 
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Figure 1. Predicted AS exponent distributions and central tendencies based on NLS with different weightings and LL-LR based on 
data set that includes humans 
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     For the second analysis based on the data set  which does not includes human CL values, the 
human CL prediction performance was assessed by three types of statistical measures, namely, 
AAFE, AFE and percentage of fold-error out of ranges as shown in Table 2 and Figure 2. The 
AFE and AAFE were estimated to be 0.74 and 2.92 by NLS with weighting 1/W2, which 
represents the closest estimation towards “1” for AFE and the smallest AAFE compared to other 
weightings. At the same time, the percentage of fold-errors out of ranges [0.1, 10] and [0.3, 3] 
for NLS with 1/W2 weighting method were calculated to be 7.52% and 31.6%, respectively, 
which illustrated the narrowest ranges compared to other NLS weightings tested. This trend 
could also be identified among plots (A) to (G) in Figure 2.  There were less observed data 
points located outside of the 0.3 to 3 fold lines (green lines) in NLS with weighting 1/W2 plot 
(plot (B)) compared to other NLS weighting methods. By LL-LR method, the AFE and AAFE 
were estimated to be 1.38 and 2.63, respectively, and the fold-errors out of ranges [0.1, 10] and 
[0.3, 3] were estimated accordingly to be 8.27% and 28.6%. By inspecting plots in Figure 2 
there are even less observed CLs data scattered outside of the 0.3 to 3 fold lines from LL-LR 
method (plot(A)) compared to  NLS with weighting 1/W2 (plot(B)). The overall statistics showed 
that the methods with performance were ranked by LL-LR and 1/w2 > 1/w3 and 1/w4 > 1/w1.5 > 
1/w > 1/w0.5.  The NLS with 1/W2 weighting and LL-LR were considered to demonstrate similar 
human CL prediction precision and accuracy in this study.  
     Between LL-LR and NLS with weighting 1/w2, the AFE (bias) was at 1.38 and 0.74, 
respectively, which suggested LL-LR generally over-predicts CL, while NLS (weighting 1/w2) 
under-predicts CL. Therefore, retrospectively, an additional empirical method was proposed. The 
proposed method is performing AS by LL-LR and the NLS with weighting 1/W2 separately. As a 
following step, for each compound in the data set, the predicted human CLs based on these two 
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different approaches were averaged and the resulted value was defined to be the final predicted 
human CL. The results are shown as plot (H) in Figure 2 and in the bottom row of Table 2. This 
new proposed approach demonstrated a relatively better AFE and AAFE at 1.14 and 2.59, 
respectively. Compared to all other methods conducted in this study, including LL-LR and NLS 
with weighting of 1/w2, this newly developed empirical approach further improved the precision 
and accuracy of human CL prediction. 
     In summary, this work evaluated a wide range of NLS with weighting functions in analyzing 
the allometric function, and strongly confirmed that the application of the LL-LR is likely the 
best performing method, although the latter method is associated with many fundamental 
assumptions. At the same time, the current analysis suggests that the widely held assumption of 
log-normality of CL distribution in pharmacokinetic field is appropriate. In addition, a new 
empirical method, which averages the predictions between LL-LR and NLS weighted of 1/w2 
appeared to improve the prediction. However, this method needs more rigorous external data to 
fully evaluate it. 
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Table 2.  Human CL prediction performance comparison among NLS and LL-LR: AAFE and 
AFE, percentage of fold-errors out of ranges [0.1, 10] and [0.3, 3] 
 
Weighting function AFE AAFE % out of [0.3, 3] % out of [0.1, 10] 
1/w0.5 4.07 7.79 51.1 35.3 
1/w1 3.43 7.50 51.1 35.3 
1/w1.5 1.67 4.65 44.4 23.3 
1/w2 0.74 2.92 31.6 7.52 
1/w3 0.64 3.05 33.8 7.52 
1/w4 0.61 3.12 36.8 8.27 
LL-LR 1.38 2.63 28.6 8.27 
Mean Prediction of LL-LR and 1/w2 1.14 2.59 30.1 6.77 
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Figure 2. Observed versus predicted human CL values among different methods. The solid line 
represents the line of identity; The dashed lines indicate fold-errors at 0.3 and 3; and the black 
dots show observed CLs in different animal species for different compounds.   
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     The predictions after MLP and BrW correction on LL-LR were compared to those without 
correction by LL-LR method demonstrated in Table 3 and Figure 3. The AFE was estimated to 
be 0.7, 0.47 and 1.38 by MLP and BrW correction and direct simple LL-LR, respectively. These 
results confirmed that after MLP and BrW correction, all human CLs predictions were 
systemically downward shifted compared to direct LL-LR. The mathematical derivation by Tang 
and Mayersohn showed that there were 0.495 and 0.659 fold downward adjustment of the 
predictions by MLP and BrW correction, respectively, which was consistent with our finding in 
this study (28). This trend could also be identified in the plots in Figure 3. Compared to LL-LR 
method plot, the predicted data points were systemically downward shifted. The AAFE was 
estimated to be 2.85, 3.41 and 2.63 by MLP and BrW correction and the direct simple LL-LR, 
respectively. Apparently, precision was higher by the simple direct LL-LR approach. In addition, 
as pointed out by Tang and Mayersohn, such MLP and BrW adjustment were only dependent on 
the animal body weights among species and had no effect on the measured CL values.  
     Overall, the MLP corrected LL-LR appeared to perform similarly with simple LL-LR 
approach, while the BrW tended to over-correct the predictions. As shown in Table 3., the 
percentage of fold-errors out of ranges [0.1, 10] and [0.3, 3] for direct LL-LR method were 
calculated to be 8.27% and 28.6%, respectively, which representing the narrowest ranges as 
compared to MLP and BrW correction approaches. In addition to the intrinsic defect pointed out 
by Tang and Mayersohn towards the MLP and BrW correction method, our analysis results in 
this study indicated that performing MLP and BrW correction on LL-LR did not provide better 
human CL prediction compared to direct simple LL-LR method.   
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Table 3.  Comparison among MLP and BrW corrected LL-LR and simple LL-LR: AAFE and 
AFE, percentage of fold-errors out of ranges [0.1, 10] and [0.3, 3] 
 
Methods AFE AAFE % out of [0.3, 3] % out of [0.1, 10] 
MLP correction 0.70 2.85 37.6 6.02 
BrW correction 0.47 3.41 46.6 9.02 
LL-LR 1.38 2.63 28.6 8.27 
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Figure 3. Predicted versus observed human CLs among different prediction methods: LL-LR 
corrected by MLP, LL-LR corrected by BrW as well as LL-LR.  The solid line represents the 
line of Identity; The green lines indicates fold-errors at 0.3 and 3; and the black dots illustrate 
observed CLs in different animal species for different compounds. 
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     Based results from the second analysis, the approaches of LL-LR and NLS with weighting of 
1/W2 performed better for human CL prediction than other methods tested in this study. 
Therefore, the prediction performance versus statistics, including RMSE%, BIAS% and R2, was 
evaluated on the LL-LR method. The evaluation results, predicted human CL over observed 
human CL ratio versus each of the statistic indices, are illustrated in Figures 4 and 5. Overall, 
none of the three statistic indices showed good correlations with the prediction performance. A 
poor correlation between R2 and the prediction performance has been documented by other 
investigators (24)(25). The current analysis with a larger data size further confirmed the 
conclusion that application of R2 in guiding the allometric prediction is not appropriate. The lack 
of correlation between RMSE% / BIAS% and prediction was demonstrated in allometric analysis 
for the first time with a large data set of experimentally obtained clearance values in different 
animal species. These results further show the difficulty in assessing the allometric relationship 
and thus predicting human values with limited species numbers. From a statistical point of view, 
this makes sense as well, since any model for statistical analysis with a sample size at 3 or 4 may 
be under-powered. Therefore, the statistic index R2, RMSE% and BIAS% are not recommended 
to guide prediction performance in AS. 
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Figure 4.  Comparison of R2, RMSE%, BIAS% versus prediction fold-error (three plots) for the LL-LR method. The black dashed 
line represents the prediction ratio = 1; the blue lines represents the prediction ratio at 0.3 and 3 fold. 
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Figure 5. Comparison of RMSE%, BIAS% versus prediction fold-error (three plots) for the NLS weighted of 1/w2. The black dashed 
line represents the prediction ratio = 1 and the blue lines represent the prediction ratio at 0.3 and 3 fold. 
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Appendix 1: Example R codes for NLS and weighting 
__________________________________________________________ 
Weight function: 
wfct <- function(expr)  
{  
expr <- deparse(substitute(expr))  
 ## create new environment  
newEnv <- new.env()  
  ## get call  
mc <- sys.calls()[[1]]  
mcL <- as.list(mc)  
 ## get data and write to newEnv  
DATA <- mcL[["data"]]  
DATA <- eval(DATA)  
DATA <- as.list(DATA)  
NAMES <- names(DATA)  
for (i in 1:length(DATA)) assign(NAMES[i], DATA[[i]], envir = newEnv)  
 ## get parameter, response and predictor names  
formula <- as.formula(mcL[[2]])  
VARS <- all.vars(formula)  
RESP <- VARS[1]  
RHS <- VARS[-1]  
PRED <- match(RHS, names(DATA))  
PRED <- names(DATA)[na.omit(PRED)]  
 ## calculate variances for response values if "error" is in expression ## and write to newEnv  
if (length(grep("error", expr)) > 0) {  
y <- DATA[[RESP]]  
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x <- DATA[[PRED]] ## test for replication  
if (!any(duplicated(x))) stop("No replicates available to calculate error from!") ## calculate error  
error <- tapply(y, x, function(e) var(e, na.rm = TRUE))  
error <- as.numeric(sqrt(error)) ## convert to original repititions  
error <- rep(error, as.numeric(table(x)))  
assign("error", error, envir = newEnv)  
} ## calculate fitted or residual values if "fitted"/"resid" is in expression and write to newEnv  
if (length(grep("fitted", expr)) > 0 || length(grep("resid", expr)) > 0) {  
mc2 <- mc  
mc2$weights <- NULL 
MODEL <- eval(mc2)  
fitted <- fitted(MODEL)  
resid <- residuals(MODEL)  
assign("fitted", fitted, newEnv)  
assign("resid", resid, newEnv)  
} ## return evaluation in newEnv: vector of weights  
OUT <- eval(parse(text = expr), envir = newEnv)  
return(OUT)  
} 
nls function:  
myNls <- nls(cl~ coefficient * wt s^lope, data = temp,  
start = c(coefficient = iniCOE[i], slope = iniSLP[i]), weights = wfct(1/cl^ 2)) 
Note: Where iniCOE and iniSLP are the initial supplied values for the coefficients and exponents, 
respectively; wfct is the weighting function (CL2 in this example ). 
_________________________________________________________________________ 
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Appendix 2: Example R codes for the programming of RMSE%, BIAS% and R2 
 
 
 
myAllom <- read.csv("…\\AS_pros_III\\wo_huamn_AS\\data2.csv") 
myAllom2 <- read.csv("…\\AS_pros_III\\wo_huamn_AS\\myini-woH-WT1.csv") 
 
myAllom <- myAllom[myAllom$mdv!=1,] 
mode(myAllom) 
myAllom$cl <- as.numeric(as.character(myAllom$cl))  
myAllom$wt <- as.numeric(as.character(myAllom$wt))  
ndrug <- length(unique(myAllom$drug)) 
 
myALLomBIAS <- myAllom[!duplicated(myAllom$drug),] 
myALLomBIAS <- myALLomBIAS[,c(1,3)] 
 
myALLomBIAS <- myALLomBIAS 
#head(myALLomBIAS) 
#length(myALLomBIAS$drug) 
 
lmmycoefficient <- c() 
lmmyslope <- c() 
lmpredcl <- c() 
 
##### NEW CODE FOR RMSE and BIAS 
biaslm <- c() 
rmselm <- c() 
rs2 <- c() 
##### NEW CODE FOR RMSE and BIAS 
for (i in c(1:133)) 
{  
temp <- myAllom[myAllom$drug==i,] 
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myls <- lm(cl ~ wt, data = temp,method = "qr") 
 
myPars <- coef(myls) 
lmcoefficient <- replicate(length(unique(temp$species)), exp(myPars[1]))### NOTE: myPars[1] 
should be changed  ### 
lmslope <- replicate(length(unique(temp$species)),myPars[2]) 
lmmycoefficient <-  c(lmmycoefficient,lmcoefficient) 
lmmyslope <-  c(lmmyslope,lmslope) 
lmpredcl <- c(lmpredcl,exp(myPars[1]) * (exp(temp$wt)^myPars[2])) 
 
##### NEW CODE FOR RMSE and BIAS 
rs2temp <- summary(myls)$r.squared 
rs2 <- c(rs2,rs2temp)  
 
lmpredtemp <- exp(myPars[1]) * (exp(temp$wt)^myPars[2]) 
residtemp <- lmpredtemp - exp(temp$cl) 
biaslmtemp <- mean(residtemp)/mean(lmpredtemp)*100 
biaslm <- c(biaslm,biaslmtemp) 
 
nspecies <- length(temp$wt) 
residtemp2 <- (lmpredtemp - exp(temp$cl))^2 
rmselmtemp <- (mean(residtemp2))^0.5/mean(lmpredtemp)*100 
# rmselmtemp <- ((residtemp2/mean(lmpredtemp)/(nspecies-2))^0.5)*100 
rmselm <- c(rmselm,rmselmtemp) 
##### NEW CODE FOR RMSE and BIAS 
} 
 
myALLomBIAS$biaslm <- biaslm 
myALLomBIAS$rmselm <- rmselm 
myALLomBIAS$rs2 <- rs2 
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CHAPTER 5 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
     Allometric scaling (AS) has been widely used in predicting human clearance (CL) based on 
animal CL data. Substantial prediction errors have been commonly observed in the application of 
this method, and various modifications to AS have been proposed in the past decades. However, 
none of them have provided a broad reliable improvement in prediction of human CL. There has 
been great controversy about how to use AS, mainly on whether to use fixed-exponent AS or 
varying-exponent AS. For fixed-exponent AS, researchers are also divided on which exponents 
and which species to use.  
      In this study, a nonlinear mixed effect modeling (MEM) approach was conducted on a large 
data set collected from the literature (number of compounds  = 251), including intravenous 
pharmacokinetic parameter (CL) values in humans and rat or dog or monkey (at least three 
species including humans). The estimated central tendency and distribution of AS exponent were 
generally consistent with literature reports and strengthens the confidence of applying commonly 
accepted allometric exponents. Polar surface area (PSA) was the only covariate identified as a 
statistically significant covariate for the AS coefficient by explanation of 3% of inter-drug 
variability for AS coefficient. However, this finding may not have much practical usage to 
significantly affect the prediction of human CL by AS. Overall, with the largest data set reported 
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in the allometric field of pharmacokinetics and the rigorous analyses on the correlations of the 
physiochemical properties and allometric relationship, this work shows little or no impact of 
physiochemical covariates on the allometric predictions of clearance.  
     In this study, single species AS was also systemically investigated using the same data. The 
estimated single species AS exponents were consistent with the literature reports and the 
commonly used single species AS exponent values. There were no obvious correlations 
identified between the estimated AS exponents and the physicochemical properties or 
pharmacokinetic properties of the compounds. For a hypothetical compound under drug 
development, stochastic simulations, based on the uncertainty obtained from the data and 
modeling results from this work, were performed to capture the uncertainty in the predictions of 
human CL from single species methods. The population results obtained provided a framework 
in incorporating the uncertainty in allometric scaling using single species, which is 
recommended in real world practice.  
     Evaluation and cross comparison were conducted for the statistical methodologies in 
analyzing allometric functions, namely the log-log transformation followed by linear regression 
(LL-LR) and direct nonlinear regression (NLS) with different weighting schemes. The LL-LR 
method and the NLS with 1/CL2 weighting resulted in the most similar allometric exponent with 
central tendency around 0.668.  This value is close to what has been reported in literature. In 
addition, these two methods provided the best predictability among the different methods, which 
supports the widely used LL-LR method used for pharmacokinetic interspecies scaling. 
Furthermore, the statistic indices, R2, RMSE% and BIAS%, were all shown to bear poor 
correlations with the prediction performance. Lastly, LL-LR analysis corrected by MLP and 
BrW were demonstrated to be no better, or even worse, than the direct LL-LR method.  
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     The knowledge gained from this work should contribute to a better understanding of the 
variability in AS exponents and better practice in performing AS in human CL prediction. The 
intensive data analysis with a large data set collected in this work did not indicate any 
physicochemical and DMPK parameters that would help to explain inter-drug variability in 
allometric exponent and reduce prediction errors. These results were not entirely surprising as 
clearance by nature is a biological process, which involves with the metabolic enzymes and/or 
transporters for most drugs that are not eliminated by passive excretion like renal filtration.  It is 
well accepted that drug distribution is more likely to be impacted by the compounds 
physiochemical properties. For example, many reports have successfully showed the in silico 
prediction of steady-state volume of distribution (Vss) based on physiochemical properties alone. 
On the contrary, there are no publications or models that show reliable and acceptable prediction 
of clearance based on physiochemical properties. Therefore, future work, seeking to explain the 
allometric relationship, should focus on the parameters that reflect the biological processes. For 
example, the interspecies difference in the metabolic activities, such as CYPs, should be 
systemically investigated with regard to the in vivo allometric relationship. Of course, this type 
of data needs more intensive experimentation and literature searching and evaluation, as for each 
compound under investigation, the elimination routes and major metabolic pathway need to be 
clarified. Overall, allometry has been an empirical and useful prediction tool, and it will continue 
to be valuable in the field of human PK prediction. However, more mechanistic investigations, in 
conjunction of rigorous statistical analyses as reflected in this work, should be invested in this 
field. 
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